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Previous studies for treating Patellofemoral Pain Syndrome (PFPS) are 
controversial regarding the effectiveness in alleviating anterior knee pain (AKP).  The 
muscular imbalance between the vastus medialis oblique/vastus lateralis (VMO/VL) may 
be the underlying mechanical issue causing PFPS.  It is hypothesized that Botox can 
decrease the force production capability of the lateral musculature mechanically similar 
to surgery.   Strengthening the VMO while using Botox treatment can alleviating the 
muscular imbalance that occurs with subjects with PFPS.   
A double blind study, having all participants blinded and uninformed of the 
injection contents, was implemented to test this hypothesis testing three female subjects.  
Four knees were treated.  One subject received the Botox treatment and serially a placebo 
injection in the other limb.  Two other subjects received placebo injections.  EMG was 
executed to evaluate functional testing and the performance of the injections during 
extension exercises.  Electromyography (EMG) data were collected from the muscle 
groups while the subjects performed forceful knee extension activities on an isokinetic 
dynamometer.  In addition, kinetic jump data and self-reports of pain and activity were 
collected.  Data were collected four times during a 12-week period. 
The subject who received Botox injections expressed a significant decrease in 
reported PFP and an increase in daily activities. Botox  was safe and effective in 
eliminating anterior knee pain.  The VMO and VL resulted in similar fatigue indices at 
the completion of the 12- week study.  The VMO and VL both resisted fatigue during at 
week 12.   
This document was created in Microsoft Word 2007. 
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Chapter 1: Introduction 
 
A.  Overview of Patellofemoral Pain syndrome 
 
Patellofemoral pain syndrome (PFPS) is experienced by over 2.5 million Americans 
(Bentz, 2007) and is the leading cause of knee pain in patients under the age of 45.  In addition, 
patellofemoral pain syndrome (PFPS) dominates knee ailments in regards to overuse injuries.  
According to a two-year study completed in 2002 by the University of British Columbia, 46 
percent of more than 2,000 runners experienced severe PFP (Scott, 2007).  Although the etiology 
of PFP remains elusive, strengthening the associated musculature can be effective in reducing 
chronic and episodic exacerbations of pain at the patellofemoral joint (PFJ) (Bentz, 2007). 
Patellofemoral Pain syndrome is a term commonly used to describe a musculoskeletal 
condition that is characterized by anterior knee pain (AKP) (Ng, 2002).  The pain is typically 
insidious in onset and affects the PFJ.  The PFJ is defined as the articulation of the patella with 
the femoral condyles of the femur.  The patella is part of a joint complex that includes the 
tibiofemoral joint and the tibiofubular joint (Ng, 2002).  It provides a mobile yet firm site for 
ligaments and tendons to attach on the anterior side of the knee.  The patella acts as an 
anatomical pulley and provides improved mechanical advantage to the tibiofemoral joint by 
increasing the ability of the quadriceps muscles to produce extension torque.  The health of the 
quadriceps muscle complex is important for proper function of the patellofemoral joint. 
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The quadriceps muscle complex consists of the rectus femoris, the vastus lateralis (VL), 
vastus intermedius, and vastus medialis (VM).  The locations of the muscles of interest and the 
patella are illustrated in figure 1. 
 
Figure 1:  Right Leg Illustrations for Key Points of Interest 
 
           
 
 
 
 
 
 
 
 
The rectus femoris muscle is the most superficial muscle of the quadriceps muscle 
complex. The vastus intermedius muscle is under the rectus femoris muscle and lies between the 
lateralis and medialis muscles.  The VL lies lateral to the body of the femur (Ng, 2002), while 
the VM fibers are positioned medially from the longitudinal axis of the femur.  The VM can be 
subdivided into the vastus medialis longus (VML) and the vastus medialis oblique (VMO) based 
on their fiber orientation.  The VML is oriented more vertically similarly with the other rectus 
femoral fibers, whereas, the VMO is obliquely oriented at 55° off the longitudinal axis of the 
femur, thus distinguishing the muscle group from the other vasti muscles (Farahmand, 1998).  
A B
Figure 1:  A.  The figure above represents the four muscle groups of the quadriceps 
complex.  B. Anterior view of the right leg illustrating the location of the muscle 
groups and tendon within the patellofemoral joint. 
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The fiber orientation of the VML make it better suited to contribute to knee extension torque.  
The VMO fiber orientation allows it to play a role in stabilizing the patella during extension 
activities.  However in subjects with PFPS, the VMO may be proximally positioned and 
abnormally oriented.  When the VMO muscles pull vertically in their line of action with the 
other rectus femoris muscles the oblique line of pull is reduced.  Unlike its vertical oriented 
counterparts, the VM is considered to be the weakest and most vulnerable muscle to atrophy of 
the extensor mechanism because it is the only quadriceps muscle to have an oblique line of pull; 
the position can be affected causing PFPS (Sanchis-Alfonso, 2006).  This is a recognized as a 
contributing factor in PFP patients with abnormal patellar movement (Ng, 2002 & Vicente, 
1993). 
Soft tissue structures can also contribute to abnormal patellar movement.  These are 
tissues include the iliotibial band (ITB).  The ITB is a fibrous band whose origin is near the hip, 
proximal of the gluteus maximus and minimus muscles.  As the band descends, it splits medially 
and laterally forming the IT tract. This tract blends with the VL muscle and contributes to lateral 
pull on the patella.  Excessive lateral pull on the patella can create exacerbate patellofemoral pain 
syndrome. 
The etiology of PFPS has been reported to transpire with women more than men due to 
their anatomical pelvic structure (Sanchis-Alfonso, 2006).  Women tend to have a wider pelvis.  
This can result in a greater lateral pull on the patella due to the resulting lower extremity 
geometry.  It is believed that women suffer from PFPS more than men, in part, due to this 
geometric difference (Fredericson, 2006).  The Q-angle is defined as the biomechanical Q-angle 
is defined as the angle between the line of pull from the patellar tendon to the anteriosuperior 
iliac spine and the resultant vector from the middle of the patella to the anterior tibial tuberosity 
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on the tibia (Fredericson, 2006).  The line-of-pull of this muscle group creates an oblique pull 
that forms a laterally obtuse angle which is called the quadriceps, or Q, angle as shown in figure 
2.  The Q angle is normally small, approximately 10-15° in extension and is 0° in flexion when 
the femur rotates laterally with respect to the tibia (O’Brein, 2001).  The reduction in Q-angle is 
associated with a valgus patellar force during quadriceps muscle contraction (Fox, 1993).  The 
VMO vector forces can counteract the strong VL forces stabilizing the patellofemoral joint. 
The patella relies on the balance of the quadriceps muscles and soft tissue structures to 
control medial and lateral tracking during the demands of daily activities.  When patellar 
movement is compromised, normal activities can lead to shearing and compressive forces that 
may contribute to pain (Ng, 2006).  Normal walking can produce compressive forces across the 
tibiofemoral joint exceeding five times body weight (BW) (O'Brien and Fox, DATES). For the 
same activity, forces at the PFJ are only about ½ x BW.  However, other common daily activities 
increase PFJ forces significantly. Examples include: (1) ascending stairs  PFJ forces equal 1½ 
x BW, (2) descending stairs  PFJ forces equal 3 x BW, (3) squatting  PFJ forces equal 7.6 x 
BW, and (4) jumping  PFJ forces can exceed 20 x BW (Ng, 2002).  Inappropriate alignment of 
the patella during these activities can strongly influence pain symptoms.  Other factors that 
reported to contribute to PFP include: tight gastroconemius and quadriceps muscles, delayed 
VMO activation, hypermobility of the patella, and decreased power of the quadriceps muscles 
(Ng, 2002).  
Patellofemoral misalignment and poor patellar tracking have been correlated with PFPS.  
Forces produced by the VL muscle may cause lateral patellar tracking and increase compressive 
forces under the lateral patellar facet. This weight-bearing facet is already under greater contact 
pressure than the medial facet (REF).  The line-of-pull of the VMO muscle tends to counter this 
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affect.  Any mechanical relationships or activation of these muscles can produce alteration of the 
tracking that may increase pain (Grelsamer & McConnell, 1998 and Ng, 2002). 
 
B.  Current Treatment Options for PFPS 
 
There are several ways currently employed in the treatment of PFPS.  One rehabilitation 
program incorporates taping techniques to improve patellar tracking.  In this technique, 
Kinesiotape (an elastic tape) is applied over the patella to pull it in a medial direction.  It is 
thought that this temporarily relieves the PFP if the pain was caused by maltracking and the 
associated increase lateral patellar pressure.  This allows the patient to strengthen the medial 
muscles, stretch lateral structures, and restore balance to the system (McConnell, 1986).  When 
muscle balance is restored, it is hoped that the tape is no longer necessary.  The McConnell 
patellar taping program is intended to correct patellar tracking by medializing the patella.  
The McConnell taping method (Grelsamer and McConnell, 1998) and physical therapy 
(rest, ice, or combination) are the often the first measures taken to reduce PFP. Another method 
of treatment is muscle stimulation.  In this technique, medial muscle groups are electrically 
stimulated at a low frequency.  The treatment is done daily for up to 8 weeks in hopes of 
improving the force production characteristics of the VM muscle. This treatment method has 
been reported to have some positive outcomes (Kannus, 1999). 
A surgical method of treating PFPS is termed a lateral release.  In this procedure, lateral 
retinaculum of the patella is cut to reduce the lateral forces produced by this fibrous tissue (Fox, 
1993).  Following recovery, it is hoped that the patella will track in a more normal fashion thus 
reducing PFP. 
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All of the aforementioned treatment methods for PFPS have one thing in common; they 
are all attempting to correct a mechanical imbalance in forces surrounding the patella that are 
thought to contribute to the patient’s reports of pain.  Reducing pain is ideal in any rehabilitation 
program since it allows normal movement patterns to be restored (Fox, 1993 and Fredericson, 
2006).  Each method has had limited success, but no one method has shown long term 
improvement with all patients.  A new method of treatment is being proposed in this study to 
rebalance the muscle surrounding the patella by temporarily decreasing the force production 
capability of the lateral muscle group.  It is hoped that this will decrease pain and increase the 
exercise tolerance of the patient so that force production balance can be restored. 
C.  The Nature, History, and Usefulness of Botulinum Toxin Type A 
 
Botulinum Toxin Type A, (BTX-A), is more commonly known as Botox (Botox, 
Allergan, Irvine, CA).  Botox is a poison which acts at nerve endings and inhibits the release 
of acetylcholine, thus decreasing muscle force production.  In controlled doses, the muscular 
paralysis is reversible and can ameliorate symptoms in patients with muscle imbalances (Tortora, 
1996 & Sastre-Garriga, 2001).  When used for PFPS, chemodenervation can persist for three 
months (Lim, 2006 and Singer, 2006).  After this time, axonal branching is re-established with 
the neurotransmitter junction. 
In 2006, Allergan Inc. reported Botox had helped patients get relief from certain 
medical conditions throughout 75 countries.  Rajeev Nagi, a director of sales and marketing in 
India for Allergan Inc., claimed Botox had approximately 20,000 users in 2007 
(Botoxcosmetic.com).  Botox has been approved by the U.S. Food and Drug Administration 
(FDA) as a cosmetic treatment and to medically treat some dystonias (Sastre-Garriga, 2001).  It 
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is reported safe, but does have some potential side effects.  Users may experience local allergic 
reaction, hematomas, and burning at injection sites or anaphylactoid reaction caused by 
injections and excessive weakness that can persist for 3 to 6 months.   
 One of the problems with traditional therapies to improve the muscle balance surrounding 
the PFJ is that all of the quadriceps muscles have common neural innervations.  As a result, it is 
nearly impossible to strengthen one quadriceps muscle without strengthening all of them 
(Barney, 1980).  If isolated strengthening is required to restore overall balance in the system, 
then Botox can be used to selectively inhibit the VL muscle group. Subsequent exercise will 
strengthen the VMO muscle without activating the antagonistic VL muscle. 
 
D.  Supporting Studies 
 
Research has previously reported using Botox injections to relieve PFPS.  In 2006, 
Singer et al deemed the use of Botox as a potential treatment for AKP in an 8 female open 
labeled PFPS study.  The purpose of this study was to reduce relative overall activity of the VL 
muscle while retraining the antagonist VM muscle with 12 weeks of physical therapy.  Subjects 
reported reduced knee pain and increased participation in daily activities.  Isometric quadriceps 
muscle strength was maintained or improved at the 24-week follow-up.  This was regarded as a 
novel approach to improve patellofemoral mechanics to establish treatment efficacy. 
Another opened labeled pilot study at Virginia Commonwealth University (VCU) 
investigated the use of Botox in a male subject with bilateral PFPS.  The results showed 
improvement in power and torque generation at the knee. In addition, there was an increase in 
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VMO muscle fatigue resistance.  Following the Botox injection, pain diminished at week seven 
and had not returned at a 67 week follow-up. 
 
E.  Rationale for Study 
 
It’s theorized that PFPS, is in part caused by VMO:VL muscle imbalance.  While healthy 
knees are speculated to have a 1:1, VMO:VL EMG ratio, this ratio has been reported to be 
approximately 0.54 in PFP patients (Ng, 2006).  A value of less than 1 implies that the VMO is 
producing less force that the VL.  This altered ratio can negatively impact the biomechanics of 
the patellofemoral joint and contribute to improper patellar tracking.  It is hypothesized that 
VMO muscle weakness results in an imbalance with the antagonist VL muscle, contributing to 
maltracking (Fredericson, 2006).  The VL is the largest component of the quadriceps groupin 
subjects with PFPS (Faramond, 1998) and supplies the most power.  It pulls the patella 
proximally then laterally during extension.  If this force is not countered by the medial muscle 
group, then mechanical tracking problems can result.  The maltracking may produce pain during 
knee extension. 
Pain has a secondary effect of altering the activation timing of these muscles.  In 2006, 
Sanchis-Alfonso reported changes in VM and VL activation in subjects with PFP during 
voluntary knee extension.  The movements included both concentric and eccentric contractions.  
PFP subjects were compared to non-painful controls.  The findings showed that during 
contractions, subjects with PFP had delayed VM activation.  This would further compound the 
negative impact of muscle imbalance.  The use of Botox may be able to address the valgus VL 
Q-angle associated with PFPS by strengthening VMO muscles.  Stronger VMO muscles may 
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reduce patellar maltracking during extension and reduce knee pain.  Figure 2 illustrates the Q-
angle geometry within the PFJ along with the force vectors and insertion points for VL and 
VMO muscle groups.  Subtle alterations in summative force development and action, due to the 
inhibitory effect of BTX-A in vastus lateralis [VL] and improved activation of vastus medialis 
[VM], may potentially contribute to reduction in joint symptoms (Singer, 2006). 
 
Figure 2:  Q-angle geometry. The figure represents the Q-angle within the PFJ. “Schematic 
depiction of the force vectors acting across the PFJ to the tibial tubercle (TT) [A]. Arrows show 
relative insertions into the quadriceps tendon, which are demonstrated in the frontal plane MRI 
in a normal individual [B] (Singer, 2006). 
 
 
Reprint permission requested: 04August2008.   
Direction of pull is illustrated for the VL and VM muscle groups. 
 
The largest problem in treating patients with mechanical PFPS is the inability to isolate 
the VMO muscle and to selectively increase its force production capability.  If improper lateral 
patellar tracking is truly the cause of the PFP in these patients, then increasing the pull of the 
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VMO muscle to balance the VL muscle force would seem vital in restoring normal patellar 
movement. Past rehabilitation efforts have focused on identifying techniques to selectively 
strengthen the VMO to improve the force balance on the patella.  To date, the current treatment 
options only provide temporarily relief and do not address the underlying biomechanical 
deficiencies of the PFJ. 
 
F.  Statement of Purpose 
 
The purpose of this research study is to further test the effectiveness of Botox in the 
treatment of muscular imbalances related to PFPS.  The study extends the impact of previous 
findings by employing a closed-label double-blind protocol.  This minimizes the effects of 
examiner and subject bias on the results.  Collected data will include kinematic, kinetic, and 
surface electromyography (sEMG) to analyze mechanical, spatial and temporal relationships of 
muscle that contribute to patellar movement.  Additional self-report data will be collected from 
subjects to assess their perceived change in pain resulting from treatment. All data collection and 
utilized instrumentation were similar to unpublished pilot work.  
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Chapter 2: Experimental Methods 
 
A.  Subject Enrollment 
The study was designed using a double blind protocol approved by the VCU internal 
review board (IRB).  The IRB ensures human research conducted at the University is compliant 
with federal, state, and local regulations.  The protocol was written with an expectation that 20 
subjects would be recruited over a year time frame from a sample of convenience.  Previous 
literature using preliminary data found Botox™ treatment as a novel approach to restoring knee 
extensor muscle balance with those with PFPS.  Therefore all subjects were pre-screened by a 
licensed physician executing past literature criteria for PFPS.  After pre-screening, the subjects 
could enroll in the study if they met the following inclusion criteria: 
 18-40 years of age 
 anterior knee pain (AKP) 
 pain during at least two of the following activities: climbing stairs, hopping, 
kneeling, prolonged sitting, running, and squatting 
 the subject must have insidious onset 
 patellar pain averaging at least 4 cm on a 10 cm visual analog scale 
 knee pain for at least one month 
 pain on patellar palpation 
 
Subjects were excluded from the study if they had a history of knee surgery, dislocation, or 
clinical evidence based on history and clinical exam (See Appendix C form A). 
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Four female subjects met the inclusion criteria and were enrolled in the study.   One of 
those subjects re-enrolled in the study after her other knee became symptomatic.  She had 
already successfully completing the protocol on her first knee.  Both knees met the inclusion 
criteria for this study and were treated serially.  In total, 5 knees were treated.  Subjects were 
randomly selected to receive either Botox™ treatment or placebo control.  This random 
assignment resulted in one subject receiving Botox™ treatment.  One subject decided not to 
continue after baseline testing and was removed from the study.  The total number of knees 
treated in this study was n=4. 
 
B. Target Data 
 Two types of data were collected in these experiments; subjective and objective. The 
subjective data included questionnaires designed to assess pain and functional levels. The 
objective data included quantifiable measures of performance. 
Subjective Data  
Subjective data is defined as data supplied by the subject.  Questionnaires have 
successfully been used in anterior knee pain research to collect these data.  These include the 
Anterior Knee Pain Scale (AKPS), Functional Index Questionnaire (FIQ), Lower Extremity 
Functional Scale (LEFS), and Visual Analog Scale (VAS) (Crossley, 2004 & Harrsion, 1995). 
The AKPS is a 13-item questionnaire with discrete categories related to various levels of 
current knee function (Crossley, 2004).  The subject is asked to rate their knee symptoms in 
regards to weight bearing support, presence of a compensatory limp, muscle atrophy, and pain 
when jumping, squatting, or running.   
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The FIQ questionnaire is an eight-activity multiple-choice rating form.  Example FIQ 
questions include knee function when walking 32 blocks up to a mile.  This toll is designed to 
assess functional abilities.   
The LEFS rates exercises with a ratio scale of extreme difficulty to with no difficulty. The 
daily tasks that are rated include usual work, hobbies, bathing, walking, putting on shoes, 
squatting, lifting objects from the floor, performing light activities, getting in/out of car, walking 
2 block to a mile, ascending/descending 10 stairs, standing and sitting for 1 hour, running on 
uneven ground, making sharp turns while running fast, hopping, and rolling out of bed.   
The VAS can be used to quatify subjective data. In pain assessment, it is represented to 
the subject as a horizontal line, 10 centimeters in length, anchored by a pain descriptor at each 
end (see Appendix D). This descriptor is typically “no pain” at the left end, and “extreme pain” 
at the right end.  The subject is asked to mark their perceived pain on the line with a vertical 
mark.  The location of this vertical mark from the left end of the line is measured by the 
examiner.  This allows the data to be converted to an ordinal scale for analysis.   
Objective Data 
 Objective data is defined as data from physical exam or laboratory collection.  Functional 
measurements such as, (1) jump height, (2) isokinetic force production, (3) isometric force 
production, and (4) fatigue measures are commonly used in exercise research to quantify subject 
performance.  
 1.  Jump height 
 Force plates can be used to measure jump height.  A force plate is an instrument designed 
to measure ground reaction forces in three directions; vertical, anterior-posterior, and medial-
lateral.  They are used in biophysics and human performance research.  The plates are typically 
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mounted in the floor.  When a force is applied to the plate, deformation is relative to the 
magnitude of the force applied.  The deformation results in a proportional load cell voltage 
change (Grimshaw, 2006).  If a subject is asked to jump vertically from a force plate and land 
back on the plate, their “hang-time” (or time in the air) is proportional to the height their center 
of mass was elevated.  This hang-time can be converted to vertical jump height using the 
following constant acceleration equation: 
 
Jump height in inches = 192 (t/2)2 
 
All force plate data were sampled at 1000Hz with a 12-bit A/D converter and stored for off-line 
processing. 
 
2. Isokinetic force production 
Isokinetic testing is a reliable tool for strength assessments (Tiffreau, 2007), even in weak 
subjects.  Isokinetic means constant velocity and requires a specialized piece of equipment called 
an isokinetic dynamometer.  There are several available commercially and they are frequently 
used in rehabilitation and research settings.  The isokinetic dynamometer is an electromechanical 
device designed to quantify extremity force production by having the subject perform against a 
constant velocity load through a defined range of motion.  It is a dynamic test. A computer 
monitors force, angular velocity, and position of a rotating lever arm as the subject pushed 
against it.  The maximum angular velocity is preset by the examiner.  During isokinetic testing, 
the subject is instructed to push as hard as they can on the lever arm.  As the preset velocity is 
reached, the dynamometer compensates by increasing the resistive load against the limb.  This 
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limits the maximum velocity the subject can achieve and effectively creates an isokinetic 
environment.  Force is recorded as the dependent variable and a measure of performance.  
Variable derivatives included average work, average power, and peak torque.  In these 
experiments, the subject was set up to flex and extend their knee against the load. 
The isokinetic testing protocol involved having the subject first perform a five-minute 
warm-up on a stationary bike at a 50 watts load (Coburn, 2005).  The dynamometer (Biodex 
System 3, Biodex Medical Systems Inc, Shirley, NY) was setup for knee testing and adjusted to 
fit the subject based on the Biodex testing manual instructions (Figure 4).  The Biodex is 
designed to control velocity and reliably measure power, angular velocity, and torque (Drouin, 
2001).  The subject was securely strapped in place in a seated position to minimize compensatory 
movements.  Subjects were then asked to perform single limb concentric knee extension exercise 
at velocities of 180°/sec, 90°/sec, and 45°/sec through a range of 10°-90°.  The range of motion 
(ROM) was set using a universal goniometer and standard anatomical landmarks (axis = lateral 
epicondyle, distal reference = lateral malleolus, proximal reference = greater trochanter).  The 
lateral epicondyle was aligned with the axis of the Biodex moment arm to minimize shear force 
on the knee. 
Figure 3: Biodex system 
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The subject was allowed to practice the isokinetic activity until they felt comfortable with 
the test.  They were instructed to perform the knee extensions as quickly as possible and 
performed three sets of five repetitions.  A 60-second rest was provided between sets.  All 
isokinetic data were sampled at 1000Hz with a 12-bit A/D converter and stored for off-line 
processing. 
 
3.  Isometric force production 
Isometric force production has been used to assess muscle function in previous research 
(Coburn, 2005).  Isometric or static functional tests are used to evaluate muscular contractions at 
a fixed limb position.  Theoretically, isometric contractions occur when the muscle develops 
tension with no changes in muscle length.  In these experiments, force production was measured 
at 30°, 60°, and 90° of knee flexion.  The Biodex was held in a fixed position and the subject was 
asked to forcefully extend their knee in a sustained contraction at each angle for five second.  
The force from this maximum voluntary contraction (MVC) was recorded.  Three sets were 
performed at each angle with a 60-second rest between tests.  All isometric data were sampled at 
1000Hz with a 12-bit A/D converter and stored for off-line processing.  The force data was 
converted to torque for analysis. 
 
4.  Fatigue measures 
Fatigue is a reversible physiological phenomenon that can be measured during isometric 
muscle contractions (Ng, 2002).  This is accomplished by recording the muscle’s electrical 
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activity during the contraction.  It can be done using surface electrodes with a technique called 
surface electromyogram (sEMG).  The amplitude of the electrical activity is directly related to 
the muscle contraction force via the excitation-contraction coupling process. sEMG amplitude is 
often processed through a root-mean-squared (RMS) algorithm and has been shown to have a 
quasi-linear relationship with muscle force production (Kallenberg, 2008).   
When submaximal isometric contractions are held until exhaustion, force production 
decreased.  Findings suggest that a drop in mechanical efficiency contributes to this decline 
(Ebersole, 2008).  Subsequent changes in the RMS signal can be observed (Wnek and Bowling, 
2008).  Changes in the power spectrum of the sEMG signal can be seen as well.  The power 
spectrum is quantified by transforming time-domain data into the frequency-domain by 
employing a Fourier Transform.  As a muscle fatigues, the median frequency has been shown to 
decrease (REF). 
sEMG data collection was accomplished using a 4-channel commercial system (Noraxon 
Myosystem 1200, Scottsdale, AZ).  This is a differential system with a CMRR of > 100dB and a 
bandwidth of 10Hz to 500Hz.  Skin preparation involved cleaning the skin surface with 70% 
isopropyl alcohol and wiping it dry.  Electrode pairs were place parallel to muscle fiber 
orientation for vastus medialis oblique (VMO) muscle and vastus lateralis (VL) muscle of the 
study leg using standard anatomical landmarks for reference (Figure 5).  The VMO electrodes 
were placed superior and medial to the patellar apex a distance of “4-finger” widths.  The VL 
electrodes were placed superior and lateral to the patellar apex a distance of “one hand-breadth”.  
The electrodes for each muscle group were approximately 2mm apart.  A single ground electrode 
was placed on the lateral epicondyle. 
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Figure 4: Approximate EMG Placements for Vastus Lateralis and Vastus Medialis muscle belly 
and ground reference placements. 
 
 
  
During the fatigue testing protocol, the subject was asked to sustain an isometric 
extension contraction at 80% of their maximum for 40-seconds with their knee held in a fixed 
position (60° flexion).  Visual feedback provided a target to assist in this process. The 80% 
threshold was calculated by averaging the maximum isometric force data from the isometric 
force production trials performed at 60° of knee flexion.  The fatigue test was repeated three 
times with a 60-second rest between trials.  Verbal encouragement was provided.  All sEMG 
data were sampled at 1000Hz with a 12-bit A/D converter.  A digital 2nd order Butterworth filter 
was used to band limit the data between 20 and 200 Hz and the data were stored for off-line 
processing.  
Fatigue was quantified by processing the sEMG data with a Fast Fourier Transform 
(FFT).  The 40,000 data points (40-seconds at 1000Hz) were temporally processed in sequential 
windows of 1024 points with an overlap of 512 points.  The median frequency (MnF) in each 
window was computed and stored.  A time-indexed plot of these frequencies was created and a 
linear regression line was fit to the data.  The slope of this line is an indication of relative fatigue 
with a negative slope indicating a fatiguing process (Yassierli, 2006). 
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C.  Study Design 
The study design included five treatment sessions.  After the initial visit (session 0), data 
were collected four additional times over a 12-week period.  Each subject followed the same 
outline and basic exercise regimen. 
Session 0:   
Documentation of subject medical history, physical exam (height, weight, blood pressure, 
and temperature), and a knee exam were performed.  Data forms for inclusion, exclusion criteria, 
diagnosis, eligibility, subject name and contact information were collected.  Subjective 
questionnaires on knee pain and function were given to the subject to document their knee pain 
three days prior their testing session. 
Session 1:  (3-7 days following session 0) 
Baseline lower extremity functional and pain scale data were collected.  The subjects 
were instructed to climb one flight of stairs and descend the same flight of stairs, rating their pain 
using the VAS.  The subjects were also instructed to perform three independent vertical jumps on 
a force plate (Bertec model 4060).  After completing the jump tests the subjects they rated their 
current anterior knee pain using the VAS.  Isometric, isokinetic, and sEMG data were also 
collected. 
Subjective data were collected by having the subject complete the AKPS, LEFS, and FIQ 
forms.  In subsequent testing sessions, subjects completed this questionnaire at home, one day 
prior to arrival.  The subjects were asked to record their data around the same time of day in an 
effort to improve the consistency of this measure. 
Following the baseline testing, the subject was seen by study physician to receive 
injections of Botox™ or placebo. The pharmacy provided these materials in an unmarked syringe. 
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All examiners and subjects were blinded to the content of the syringe.  The Botox™ dose 
contained 100 units of the drug.  The placebo dose contained 1cc of saline, 1cc of 1% lidocane, 
and 1 drop of bicarbonate.  The study physician administered the injections at four VL sites 
using ultrasound imaging to guide location.  Finally, a physical therapist instructed the subject in 
the home exercise program (HEP) to be followed for the next 12 weeks.  The details of this 
program can be found in the following section (D. Home Exercise Program). 
Session 2-4:  (Visits for 4, 6, and 12-week post injection) 
Each of the next 3 sessions was the same.  The subjects were asked to complete the pain 
scaling forms three days prior to the session.  They were also asked to complete the AKPS, 
LEFS, and FIQ forms one day prior to the session.  These forms were then returned to study 
director on the day of testing.  At that time, subjects were asked if any changes in general health 
had occurred since last visit.  Jump tests, stair-climb, isokinetic, isometric, and sEMG measures 
were taken and recorded as before.  At the completion of the study, each subject commented on 
their overall improvement, consistency, or no change after treatment.  
At the conclusion of each testing day the data were exported (Appendix B).  Data 
analysis was performed with custom programs written with Matlab software (version 7.0; The 
Math works Inc., Natick, MA).  Appendix C provides the calibration formulas to convert the 
Biodex data (voltages) into real-world values.  Knee torque is defined as the Biodex load cell 
force x the length of the moment arm, where the moment arm length is the distance between joint 
center and the lateral malleolus of the subject. 
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D.  Home Exercise Program  
 
 Subjects were provided with instructions for a home exercise program.  These exercises 
were carefully selected since PFPS can be aggravated when patellofemoral compression forces 
are added to the joint.  A description of each exercise their rationale follows. 
 
The HEP included: 
 Single limb squats -- Squats isolate the VMO with medial adduction at the end of the 
squat.  Performing single leg exercises ensures equal efforts per limb. 
 Squats with hip adduction – The adduction exercises attempts to isolate the VMO.   
 Side lying abduction -- The abductions exercise attempts to isolate the VL.  
 Straight leg raises -- The straight leg raises strengthens the entire quadriceps complex as a 
whole maximizing quadriceps strength. 
 Side raise hip adduction -- The adduction exercises attempts to isolate the VMO.   
 Iliotibial (IT) band stretches -- IT band fibers blend and mix with the fibers of the lateral 
retinaculum, thus if they are tight, they can contribute to lateral patella tilting and 
excessive pressure on the patella.  The IT stretches can allow the soft tissue of the patella 
tendon to loosen around the patella structure.  It can also allow less lateral pull on the 
patella to occur with the knee, therefore, correcting or alleviating irregularities in patella 
alignment and possibly allowing relief.  When a subject can increase the number of 
repetitions over load, the muscular endurance should increase while increasing VMO 
activity. 
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Figure 5:  Exercise examples prescribed for subjects to complete daily. 
Single leg squats  Squats with adduction  ITB stretches 
            
 Side lying adductions  Side lying abductions  Straight leg raises 
                  
 
 The initial number of exercise repetitions and sets were titrated by a physical therapist 
according to each subject’s reported pain.  Each subject was asked to increase their exercises in 
repetitions or sets as they were able.  Each subject kept a diary throughout the study to record 
and to track their progress. This diary was provided to the examiner at the conclusion of the 
study. 
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Chapter 3: Results 
 
 This study included the analysis of subjective and objective data. The subjective data 
included four subject questionnaires pertaining to pain and function. The objective data included 
kinetic, kinematic, EMG, and functional measures. 
Over the course of two years, four subjects met the inclusion criteria and were enrolled in 
the study.  Three completed the protocol successfully.  One of those subjects re-enrolled in the 
study for treatment of her other knee one year after her initial testing. T his subject received the 
Botox treatment in one knee and the placebo in the other.  Data from this subject is unique and 
allows a comparison of subjective results.  Analysis of these data points will be labeled as a 
“Case Study”.  The total knees tested in this study was n=4.  One additional subject is included 
in some of the presented results.  These data are from a previous pilot study with a similar 
protocol in which the subject had both knees treated with Botox. 
Research bias was minimized by using a double blind protocol where subjects and 
researchers were blinded to the treatment type (Botox™ or placebo) during both the data 
collection and processing. Syringes were prepared by the MCV pharmacy and delivered to the 
physician unmarked.  At the conclusion of the study, one subject had received the Botox 
treatment and three had received the placebo treatment.  Throughout the remainder of this paper, 
subjects are labeled based on their injection type: Botox™, Placebo 1, Placebo 2, and Placebo 3. 
The case study data compares Botox™ to Placebo 2. 
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A. Subjective Results 
 
Subjective data is defined as data supplied by the subject.  The uses of subjective 
measures are well documented in the literature (Crossley, 2004).  These were used to assess and 
quantify pain and functional changes throughout this study.  
 
1. Anterior Knee Pain Scoring (AKPS) 
The AKPS is a 13-item questionnaire with discrete categories related to various levels of 
current knee function (Crossley, 2004). The subject is asked to rate their knee symptoms in 
regards to weight bearing support, presence of a compensatory limp, muscle atrophy, and pain 
when jumping, squatting, or running.  These questions are weighted and the subjects’ responses 
are summed to provide an overall index.  A score of zero implies severe disability; while one 
hundred represents no pain and normal function (Kujala, 1993).  Figure 6 displays the subjects’ 
AKPS results and compares subjects’ progress internally and externally over the course of this 
study. 
Figure 6: Anterior knee pain scoring for Botox treatment and placebo injections. This figure is 
a graphical representation of the data presented in Appendix A. 
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A positive change score represents an improvement in function and a decrease in reported pain. 
All subjects had a positive change score when comparing Session 1 to Session 4. The positive 
change score signifies sustainable improvement. 
 
2. Functional Index Questionnaire (FIQ) 
 The FIQ questionnaire is an eight-activity multiple-choice rating form.  The FIQ 
questions were weighted from zero to two based on the subjects’ self-reported ability to complete 
specific tasks.  The task scores were summed to create a composite score for each testing week.  
The highest achievable score was sixteen and the lowest was zero.  A score of zero indicates the 
inability to perform all activities and sixteen indicates no issue performing any of the activities. 
Results are shown in figure 7. 
 
 
Figure 7: Functional index scoring results for the Botox treatment and placebo subjects. This 
figure is a graphical representation of the data presented in Appendix A. A higher FIQ implies 
higher function capabilities. 
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 All subjects reported an improvement in performing functional tasks when comparing 
Session 1 to Session 4. 
 
3. Lower Extremity Functional Scaling (LEFS) 
The LEFS is a 19-item questionnaire related to normal daily activities. The ability to 
perform these activities is objectively defined using the following criteria (Brinkley, 1999): 
 0 = the subject was unable to perform activity 
 1 = the subject had quite a bit of difficulty performing the activity 
 2 = the subject had moderate difficulty performing the activity 
 3 = the subject had a little bit of difficulty performing the activity 
 4 = the subject had no difficulty performing the activity  
The sum of the scores was divided by the maximum possible points to create a percent composite 
score. The maximum obtainable score for LEFS is 76 points. A subject who experiences no 
difficulty with all 19 tasks would score a 100% as their LEFS result. Results are plotted in figure  
 
 
 
 
 
 
 
8.  
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Figure 8A: Illustrates the LEFS results for the Botox treatment and placebo subjects. The 
Botox subject had a change score of +22%. The Placebo subjects had an average change score 
of +8%. This figure is a graphical representation of the data presented in Appendix A. 
 
 
 
The subject treated with Botox had the highest overall score experiencing only mild 
difficulty performing squats, running on uneven turf, and making sharp turns while sprinting. All 
subjects were able to perform daily tasks, such as rolling in bed and getting in and out of the bath 
and vehicle. However, the placebo subjects reported extreme or mild difficulty with recreational 
activities, such as walking two blocks to a mile, squating, running on uneven turf, and making 
sharp turns while sprinting.  
 
When comparing the Case Study results, the limb treated with Botox initally had a total 
score of 69%, but following treatment, progressed to 91% by week 12. The subject experienced 
little difficulty with 3 out of the 19 tasks. However, when the same subject later received the 
placebo treatment on the other leg (Placebo 2), the subject initally scored 80% and received a 12 
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week score of 81%, noting performance difficulty in 8 out of the 19 tasks. A comparision 
between the placebo control injective limb resuted in a higher rating of five points versus the 
Botox treated limb. These tasks included recreational activities, squatting, walking 2 blocks to 
a mile, sitting and standing for an hour, running on unven turf, and making sharp turns while 
sprinting. 
Figure 8B: Illustrates the LEFS results for the Case Study subject. The Botox subject had a 
change score of +22%. The Placebo2 had an average change score of +1%. This figure is a 
graphical representation of the data presented in Appendix A. 
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4. Visual Analog Scaling (VAS) 
 VAS is a measurement tool to assess knee pain characteristics that cannot be directly 
measured using other instruments (Gould, 2001).  The amount of pain a subject feels ranges 
across a continuum from “no pain” to “extreme pain”.  The assessment is highly subjective and 
most valued when looking at change within subjects.  These data are of less value for comparing 
across subjects (Gould, 2001).  Figure 9 illustrates the VAS results for ascending and descending 
stairs and jumping for the subject treated with Botox, averaged placebo, and case study data.  
 
Figure 9: VAS Results for subject treated with Botox™. 
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The Botox subject perceived pain scoring diminished throughout the study for 
ascending and descending stairs and while jumping. Initially, pain was reported to be in the 
moderate to severe range. At the conclusion of the study, the subject reported no pain. The 
placebo controls continued to report mild pain at the end of the study. 
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C. Objective Results 
 
 Objective data is defined as data from physical exam or laboratory collection. Functional 
measurements were used to quantify subject performance. Testing was accomplished using an 
isokinetic dynamometer (Biodex), a surface EMG system (Myosystem 1200, Noraxon), and a 
force plate (Bertec). Data were again collected four times during the course of the study at weeks 
1, 4, 6, and 12. Results are reported below. 
 
1. Isokinetic Results 
Concentric isokinetic leg extension data were collected using a Biodex isokinetic 
dynamometer (Biodex Inc, NY). Subjects were then asked to perform single limb concentric 
knee extension exercise at velocities of 180°/sec, 90°/sec, and 45°/sec through a range of 10°-90° 
of knee flexion. Intra subject data were averaged for each velocity. No verbal encouragement 
was provided during data collection to allow each subject to define their personal maximum 
effort. Work and power were calculated for each trial. The results are summarized in Appendix  
 
a.  Work 
Work is defined by Newton’s Second Law of angular motion. The law states that 
a net torque produces angular acceleration of a body that is directly proportional to the 
magnitude of the torque, in the same direction as the torque, and inversely proportional to 
the body’s moment of inertia. This law is often stated as, "torque equals moment of 
inertia times angular acceleration (T = I)". Like its linear analog, the expression of for 
angular work is a function of force and distance moved: 
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W =  T x θ  
Where:  T is torque in N-m and θ is the angular displacement in radians. 
Work is measured in joules (J), which is defined as Nm or kgm2/s2. 
 
When using the Biodex during knee extension activities, torque is produced by 
the subject when they apply a force to the rotating arm at some distance from the axis of 
rotation. Work is done when this torque produces angular movement of the arm. This can 
also be expressed as rotational kinetic energy (RKE = ½ I2; where I = the moment of 
inertia, and  = the angular velocity in radians/sec). Figures 10A-D illustrate the angular 
work done in order of 180°/sec, 90°/sec, and 45°/sec using the work energy theorem. 
Average work, power, and standard deviations are presented in Appendix A9. 
 
Figure 10A: Work results at 180°/s.   
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Figure 10B: Work results at 90°/s.   
 
 
Figure 10C: Work results at 45°/s 
  
    
Figure 10D: Work results at 45°/s for Case Study 
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 In general, angular work was greater at the lower angular velocities for all subjects. The 
Botox™ subject had a significant decline in angular work following the injection.  
 
b. Power 
 Power is the product of torque and angular velocity. Power is defined as the amount of 
work performed per unit time (Cutnell and Johnson, 1997) and expressed at Nm/s (or Joules/s or 
Watts).  
P =  T x   
Where:  T is torque in N-m and  is the angular velocity in radians/sec. 
  
Figures 11A - D illustrate power results from kinetic angular motion testing at 180°/s, 
90°/s, and 45°/s. 
 
Figure 11A: Power results at 180°/s 
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Figure 11B: Power results at 90°/s 
  
 
 
Figure 11C: Power results at 45°/s 
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Figure 11D: Power results at 45°/s for Case Study 
 
 
 
 The power results illustrate more variability at the higher velocity with higher power 
generation at these velocities. The Botox™ treated subject was less powerful at week 4, but 
recovered by week 6. 
 
2. Isometric Results 
 Using the Biodex to perform isometric contractions, torque was measured at prescribed 
angles. Torque is defined as: 
Torque (τ)  =  Fι     (Cutnell and Johnson, 1997) 
Where: F is the magnitude of force and ι is the lever arm  
Torque is measure in Newton * meter (Nm) 
Isometric extension torque production was measured and recorded for orthopedic knee 
angles at 30°, 60°, and 90° of flexion. The isometric data for each subject was averaged for all 
trial sets. Results are plotted in figures 12A-C and the subjects averages are reported in appendix 
C.  
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Figure 12A: Botox™ subject torque results at 30.  This figure is a graphical representation of the 
data presented in table 4. 
 
 
 
Figure 12B: Placebo torque results at all three isometric testing angles 
 
 
Figure 12C: Case Study torque results at 60° 
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There is a similar pattern at all three isometric contraction angle.  However, the ability to 
produce knee extension torque is maximized at a knee angle of 45° due to muscle length 
physiology and anatomical mechanical advantage, so it is expected that the torque levels at 30° 
and 60° would be greater than at 90°.  Each subject increased their torque production over time 
with the highest amount of torque produced during the final week of testing.  
 Both the Botox™ and placebo limbs increased torque production at week 4, with the 
exception of placebo 3 in the 30° trail.  The Botox™ treated limb produced the highest torque at 
60°, but the placebo control 2 produced the highest overall torque. 
 
3. EMG 
 Electrodes were placed on each subject to measure VL and VMO muscle electrical 
activity during a sustained isometric contraction.  The data was processed with a root-mean-
square (RMS) algorithm to allow averaged magnitude data to be used to compute an activation 
ratio (VMO:VL).  The RMS process involved full wave rectification of the EMG data, followed 
by digital integration using a 25ms time constant.  Typical results are illustrated in figure 14A.  
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Figure 13A: The three plots in figure 13A illustrate typical sEMG responses during the isometric 
testing.  Note that torque production was constaint during the contraction.  Also note that the raw 
EMG data is presented in blue and the RMS data is presented in red. 
 
 
 
In figure 14A, the top figure illustrates the production of knee torque initiated around 3 
seconds and ending after 9 seconds.  The middle plot illustrates typical sEMG results for the VL 
muscle.  The bottom plot illustrates a typical sEMG response for the VMO muscle. From these 
data, EMG ratios were computed from the middle 3 seconds of contraction data.  This was done 
by dividing the average RMS VMO value by the average RMS VL value.  Isometric contractions 
were tested at 30°, 60°, and 90° of knee flexion.  In figures 14A and B, VMO:VL EMG signal 
ratios are illustrated at 60°.  These ratios were used to report relative muscle activity for all trials. 
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Figure 14A: VMO:VL EMG signal result ratio for Botox™ and the placebo controls averaged 
data at the 60 ° position. 
 
  
SEM was 0.043 for VMO/VL for placebo control ratios.  Small values signify that the 
means for each placebo differ by 0.043.  This implies a consistency within the placebo data. 
  
These data suggest that the VMO was more active that the VL muscle at week 6 in the 
Botox™ treated subject.  This ratio returned to baseline by week 12.  The average placebo data 
showed no change over the course of the treatment.  Figure 14B illustrates a similar trend in the 
Case Study comparison. 
Figure 14B: VMO:VL EMG ratio results for Case Study comparison. 
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4. Fatigue 
Muscle fatigue can be quantified by measuring a shift in sEMG median frequencies 
(MnF) during a sustained isometric contraction.  This shift to lower frequencies can be quantified 
as an index of fatigue.  Figure 15A is a typical response plot during VL fatigue analysis.  
 
Figure 15A: Typical sEMG data from the VMO muscle during a sustained (40s) 
isometric contraction. 
 
 
 
The top plot illustrates raw sEMG data. The rectangular window (at the 5 second data 
collection time) denotes the data used in the FFT analysis shown in the bottom plot.  The FFT 
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data was used to compute the MnF which is represented as a vertical red line.  The FFT 
calculation was sequentially executed though the temporal sEMG data stream, providing a series 
of MnF values.  These values were plotted and a liner regression line was fit to the points.  An 
example of this process is illustrated in Figure 15B. 
 
Figure 15B: Typical sEMG median frequency shift for 3 trials of subject Placebo 3.  
 
 
 
The average slope was recorded as an “index of fatigue” with a more negative number 
indicating an increase in fatigue rate.  This index is plotted for each session (data collection 
point) and can be seen in figures 15C and 15D.  Note that the Botox™ data includes pilot study 
results. 
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Figure 15C: VL Fatigue Differences from baseline. Botox™ data includes pilot study results. 
 
 
Figure 15D: VMO Fatigue Differences from baseline. Botox™ data includes pilot study results. 
  
  
The subject who received Botox™ treatment did experience more VL fatigue than 
subjects who received the placebo.  The VMO appeared relatively unchanged in the Botox™ 
subject, with fatigability increasing in the placebo subjects. 
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5. Functional Testing  
a. Force plate results 
Force plates were used to estimate vertical jump height performance.  Figure 16A 
illustrates a force plate similar to the one used in this study.  The formula used to determine jump 
height was based on the amount of time each subject was suspended in the air.  The equation 
used for the jump tests results was: 
 
Jump height (in inches) = 192 (t/2)2  
Where: 192 = a constant based on constant acceleration equations 
  t = time in seconds that the subject is airborne 
 
Longer suspension times represent higher jump height.  Averaged flight time during each testing 
period with their standard deviation is reported in the appendix. 
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Figure 16: A. An illustration of a typical force plate jump test exercise. B. Illustration of a jump 
test plot using motion monitor for research after a jump test on a force plate. C. Subject results 
for force plate jump test trials. 
 
 
A.   B.  
 
In figure 16A, when the subject leaves the force plate, as seen at 3 seconds, there is a loss 
of foot to force plate contact (the subject becomes airborne).  The subject returns to the force 
plate at the 3.4 second time point.  In this example, with the subject airborne for 0.4s equates to a 
jump height of 7.68 inches.  Figure 16C illustrates average jump data from 3 trials at each 
session. Raw data, averages, and their standard deviations are reported in appendix C. 
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Figure 16C: Jump height changes. 
 
 
The Botox™ subject improved in jump height over the course of the study.  When 
comparing baseline to final testing point, the subject who received Botox™ improved in total 
jump height by +1.91 inches, placebo 1 by +2.73 inches, and placebo 3 by +0.63 inches of a 
difference in vertical jump height.  Placebo 2 had a total jump height difference of -0.19 inches 
in jump height.  Recall that the Botox™ subject and placebo 2 was the same person.  The case 
study data shows that the Botox™ treatment resulted in a jump height 2.10 inches higher than the 
placebo treatment. 
 
b. Weekly Exercises 
 Weekly exercises were directed by a physical therapist.  The subjects were to follow 
physical therapists instructions off site.  Any issues completing exercises were to be 
communicated with the physical therapist.   
Figures 17A-F illustrate weekly exercise compliance (in repetitions) and pain scores. 
Repetitions and perceived pain were averaged for a weekly total score. Pain scores were based 
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on 0, being no pain, and 10, being the most excruciating pain. Subjects were asked to increase 
the number of exercise repetitions as tolerated. 
 
Figure 17A: Weekly exercise result plots for single leg squats illustrating repetition and 
perceived pain. 
 
  
Botox ™ (pain rating decreased 6 to 1)  Placebo 1 (pain rating decreased 7 to 2) 
  
Placebo 2 (pain rating decreased 4 to 2)  Placebo 3 (pain rating fluctuated) 
 
All subjects were able to maintain the prescribed, (3 repetitions as suggested by the 
physical therapist), repetitions for single limb squats.  Performing single limb squat enables each 
limb to work at their full potential without assistance from the other limb throughout the 
exercise.  The subject receiving Botox™ treatment was able to increase from two to seven 
repetitions.  This was a unique pattern only seen with the Botox™ treatment.  Pain also 
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decreased five points over the course of the study.  The placebo subjects showed a fluctuating 
pattern of perceived pain for this set of exercises.  
 
Figure 17B: Weekly exercise graphs for squats with adduction based on repetition and perceived 
pain. 
 
  
Botox™  (pain rating decreased 6 to 1)     Placebo 1 (pain rating decreased 5 to 2) 
 
  
Placebo 2 (pain rating decreased 7 to 2)  Placebo 3 (pain rating fluctuated)  
  
In figure 17B, all subjects were able to maintain the prescribed repetitions for squats 
with adduction. The exercise requires the subject to maintain a 90 ° angle at the knee joint with a 
slight push inwards while performing squats.  Three out of the four subjects were able to 
increase their repetitions. The subject receiving Botox™ treatment in one limb and placebo 
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control in the contralateral limb (placebo 2) both decreased pain by five points. A three point 
decrease was achieved with placebo 1. Placebo 3 had fluctuations in pain rating throughout the 
course of the study with a one point difference in pain. 
 
Figure 17C: Weekly exercise graphs for IT band stretches based on repetition and perceived 
pain. 
 
 
Botox™  (pain rating decreased 1 to 0)    Placebo 1 (pain rating decreased 6 to 0) 
 
Placebo 2 (pain rating unchanged)   Placebo 3 (pain rating not reported) 
 
 In figure 17C, the ten prescribed IT band stretch repetitions were maintained throughout 
the study. The Botox™ treatment subject and placebo 1 had decreases in their ITB pain. Placebo 
2 remained at a three out of ten pain scale, while placebo 3 did not report any pain levels. 
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Figure 17D: Weekly exercise graphs for side lying abductions based on repetition and perceived 
pain. 
 
 
Botox™  (pain rating decreased 5 to 1)    Placebo 1 (pain rating decreased 4 to 1) 
 
Placebo 2 (pain rating decreased 5 to 2)   Placebo 3 (pain rating decreased 2 to 1 with fluctuations) 
 
 As represented in figure 17D at week 4, the Botox™ treated subject had increased the 
quantity of repetitions for side lying abduction. All placebo control subjects maintained the 
original prescribed two repetitions throughout the study. The subject treated with Botox™ also 
had a 4 point reduction in pain. The placebo controls had a two point average reduction in pain 
rating for side lying abductions. 
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Figure 17E: Weekly exercise graphs for straight leg raise based on repetition and perceived pain. 
 
 
Botox™  (pain rating decreased 7 to 2)    Placebo 1 (pain rating decreased 6 to 3) 
 
Placebo 2 (pain rating decreased 6 to 2)  Placebo 3 (pain rating decreased 5 to 1) 
 
In figure 17E, the subject who received the Botox™ treatment increased their straight leg 
raise repetitions by one at week 4. The other subjects maintained the prescribed two repetitions 
throughout the study. The subject treated with Botox™ also had a five point reduction in pain. 
The placebo controls each had a four point reduction in pain. 
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Figure 17F: Weekly exercise graphs for side lying leg adduction based on repetitions and 
perceived pain. 
 
 
Botox™  (pain rating decreased 4 to 1)    Placebo 1 (pain rating decreased 5 to 2) 
  
Placebo 2 (pain rating decreased 4 to 0)   Placebo 3 (pain rating decreased 4 to 0) 
 
In figure 17F, the subject who received the Botox™ treatment increased the side raise 
adduction by one repetition at week 4. The other subjects maintained their original prescribed 
three repetitions throughout the study. Both the Botox™ treated subject and placebo 1 had an 
overall three point reduction in their pain, while placebos 2 and 3 had a four-point reduction in 
their pain. 
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6. Summary of Results 
 Tables 1 summarize the intra and inter subjective data for the tests that displayed 
noticeable changes in outcome responses. 
 
Table 1: Summary of Treatment outcomes following Vastus Lateralis Injections 
 Botox™ Placebo 1 Placebo 2 Placebo 3 
Baseline Pain stair ascending 
VAS versus post-injection 
VAS (-10) 
6-0 (no pain) 2-1 6-2 5-0 
Baseline Pain stair 
descending 
VAS versus post-injection 
VAS (-10) 
4-0 2-0 5-3 1-0 
Baseline Pain jumping 
VAS versus post-injection 
VAS (-10) 
5-0 (no pain) 2-2 7-3 7-1 
Lower Functional 
Scale Change 
 + 23 + 8 + 1 + 16 
Anterior Knee Pain 
Scale baseline - 12 weeks 
75 - 95 57 - 72 73 - 81 69 - 91 
Functional 
Improvement 
Greatly 
improved 
No change Somewhat 
better 
Somewhat 
better 
Injection Botox Placebo Placebo Placebo 
 
For the VAS, the treated subject experienced the greatest range of pain loss when 
ascending and descending stairs.  Placebo controls 1 and 3 also reported a final pain level of 0 
cm on the VAS for descending stairs, but reported lower baseline ratings.  The scale of change 
was identical to that of the Botox™ treated subject.  
The highest possible rating was an 80 for the lower extremity functional scaling (LEFS).  
The higher valued change indicated the subject was closer to achieving a perfect score.  The 
Botox™ treated subject resulted in the highest value of LEFS change and also experienced the 
greatest increase in lower functional tasks such as sitting, their typical work and activities.  
    
 
 
 
54
Placebo control 3 also reported a large improvement in knee function with placebo 2 and placebo 
1 (see appendix C for questionnaires) rating the lowest functional improvement.  
The highest possible score that could be obtained in the AKP scale was 100.  The higher 
score would indicate no functional knee deficiencies or pain.  A 20% improvement in AKP 
occurred with the subject who received the Botox treatment.  Placebo 1-3 improved by 15%, 
8%, and 22% respectively. 
 When including the Botox pilot data, the three limbs injected were similar in that they 
were the only individuals to report a “greatly improved” overall study global rating.  
 Table 2 highlights the objective results. 
Table 2: Report of the overall functional-testing summary 
 Isokinetic Isometric Fatigue 
Subject ID Work Power Torque VMO/VL VL VMO 
Botox ↓ ↑ ↑ ↓ ↑ ↑ 
Placebo 1 no change ↑ ↑ ↑ ↓ ↓ 
Placebo 2 ↑ ↑ ↑ ↓ ↑ ↓ 
Placebo 3 ↑ ↑ ↑ ↑ ↑ ↓ 
Pilot 1 NA ↑ ↑ NA ↑ ↑ 
 
 The subject treated with Botox was the only report of decreasing overall work 
performance.  All subjects increased in power and torque. Isometric results indicated both limbs 
in the case study decreased VMO/VL ratios.  The other placebo controls increased in VMO/VL 
ratio.  All subjects, with the exception of placebo 1, increased VL fatigue during testing.  
Whereas, the VMO an increase in fatigue was demonstrated in the placebo control group and 
fatigue resistance for the current Botox study subject and pilot subjects. 
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Chapter 4:  Discussion 
  
The purpose of this research study is to test the effectiveness of Botox in the treatment 
of muscular imbalances related to PFPS.  Without a single standard of measure to categorize 
subjects suffering from PFPS, this study utilized both subjective and objective tests.  Subjective 
data were collected in the form of questionnaires.  These were established tools with proven 
validity and are often valuable in assessing life-quality issues.  Objective data were collected 
from physical exam and laboratory experimentation.  Double blind experimental methods were 
used to minimize bias in all collected data. 
 
Subjective data 
A 10-pt change in Ankle Knee Pain Score (AKPS) reflects a functional change (Crossley, 
2004).  All subjects had a positive change score in the AKPS.  This represents overall 
improvement (or a decrease in pain) during the course of the study.  The largest change was 
reported by the subject who received the Botox™ injections (+20 pts).  The subjects who 
received Placebo injections also reported positive change, but of much smaller quantity.  In fact, 
the subject label Placebo 2 reported only a one point positive change from baseline.  Recall that 
this is the case study subject who received Placebo in one knee and Botox™ in the other knee.  
Their subjective ratings can therefore be compared and illustrate the magnitude of difference 
between the two treatments, with the Botox™ treatment producing more positive results. 
The Functional Index Questionnaire (FIQ) is an eight-activity multiple-choice rating form 
where subjects’ self-report their ability to complete specific tasks.  A score of 16 indicates no 
difficulty in performing all 8 activities.  All subjects demonstrated improvement when measured 
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using this metric.  The subject labeled Placebo 1 had the largest change score and reported 
perfect score at their final data collection point.  This conflicted with that subject’s global rating 
of “slightly better” at the completion of the study.  The FIQ data did not illustrate a difference 
between the Botox™ and Placebo treatments.  It has been reported to have poor reliability in 
some applications (Crossley, 2004). This may be one of them. 
The Lower Extremity Functional Scale (LEFS) is a 19-item questionnaire related to 
activity.  These activities range from normal daily activities to recreational exercises.  This range 
is thought to provide a good measure of overall knee function through the assessment of 
perceived pain. Task scores are converted to a percent composite score.  A subject who 
experiences no difficulty with all 19 tasks would score a 100%.  The subject who received the 
Botox injection started the study with a score of 69% and ended with a score of 91%.  These 
was a positive 22.5% overall change in performance.  The subjects receiving Placebo injections 
1, 2, and 3 showed improvements of only 7.5%, 1%, and 16% respectively with an average 
percent composite score of 73 ± 2% by the end of the study.  The case study findings were again 
very telling, revealing a twenty point overall knee functional improvement for the knee treated 
with Botox™ as compared to the Placebo as a control. 
The Visual Analog Scale (VAS) is a measurement tool to assess knee pain characteristics 
that cannot be directly measured using other instruments (Gould, 2001).  The amount of pain a 
subject feels is marked on a 10cm line.  The left end of that line is labeled “no pain” and the right 
end is labeled “extreme pain”.  Subjects were asked to ascend stairs, descend stairs, and jump, 
marking their VAS scores on a separate scale for each activity.  Following patient recording, the 
distance of the mark from the left edge of the scale was measured and recorded by the examiner. 
Crossley (2004) reported that a change of two centimeters or more considered significant.  All 
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subjects showed a decrease in pain for each activity through the course of the study. The subjects 
receiving the Placebo injection had an average decrease of approximately 3cm ascending stairs, 
2cm descending stairs, and 3cm jumping.  The subject who received the Botox injection had a 
larger change.  A 6cm decrease ascending stairs, 4cm descending stairs, and 5cm jumping.  
Although all subjects demonstrated an overall reduction in pain during all three tasks, the subject 
receiving the Botox treatment had the largest reported reduction (almost double for each 
activity). 
 All of these tests reported varying pain reduction and improved knee function for all 
subjects.  Three of these tests differentiated the Botox and Placebo subjects.  The test that did 
not differentiate (FIQ) has been previously been reported as unreliable in some applications.  The 
overall improvement of the subjects could be a reflection of increased lower extremity strength 
resulting from the imposed exercise program; however, the subject who received the Botox 
treatment is the only one who reported both diminished knee pain and a significant overall 
improvement in knee function.  The Ankle Knee Pain Score (AKPS), the Lower Extremity 
Functional Scale (LEFS), the Visual Analog Scale (VAS) appear to be the most responsive 
outcome measures for the PFPS population. 
  
Objective data 
Isokinetic 
One of the objective measures of performance used in this study was isokinetic force 
production.  Isokinetic means constant velocity. In this environment a subject is asked to actively 
extend their knee against a device (Biodex) that limits terminal (angular) velocity.  As the subject 
pushes harder, resistance is increased using a closed-loop control algorithm.  Force 
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measurements are converted to torque since that force is applied through a known moment arm 
length.  These torque measures are then converted into work and power for comparison across 
subjects and trials.  A comparison across different angular velocities provides a spectrum of 
performance characteristics. 
Isokinetic work was larger at lower angular velocities for all subjects.  This is consistent 
with the physiology of concentric (or shortening) muscle contractions and known force-velocity 
relationships.  At higher velocities, the muscle becomes less capable of producing force since it 
cannot shorten fast enough.  The subject who received the Botox™ injection had a decline in 
work at week 4.  This is consistent with the anticipated inhibitory affect of Botox™ on 
acetylcholine receptors at the muscle fiber motor endplates.  This, in fact, was the purpose of the 
study; to temporarily decrease the force production capability of the lateral muscle group (VL) 
and allow the medial group (VM) to become relatively stronger.  As the effects of the Botox 
wore off (by week 12), muscle force production returned to appropriate levels. I sokinetic work 
results did not reveal any significant difference between the study groups. 
The rate of work produced by most muscle is rarely constant.  Power is often calculated 
to compensate for rapid time-course changes in work and may be more sensitive to performance 
differences.  Power is the product of angular torque and angular velocity.  For all subjects, more 
power was produced at higher velocities, but the variability of this measure was also higher.  
This may have been due to subject instruction, limited verbal motivation during the performance 
of this task, and/or limited practice time prior to the task.  Some subjects find it difficult to use an 
isokinetic dynamometer (Biodex) at higher angular velocities and may need more practice time 
to become efficient users of this device.  At lower angular velocities, data variability was much 
smaller.  The subject treated with Botox™ again showed a marked reduction in power at week 4, 
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but showed signs of recovery by week 6.  Isokinetic power results did not reveal any significant 
difference between the study groups.  All subjects had an increase in power production at all 
angular velocities when comparing the end of the study to baseline.  Since power is a more 
robust measure of performance, this implies an improvement in performance in all subjects.  It is 
important to note that this increase does not signify a change in medial and lateral muscle 
balance, it just represents an increase in total performance (and that includes force production). 
 
Isometric 
Another objective measure often employed to assess muscle performance is isometric 
force production testing.  Isometric means constant length so these data represent force 
production against a fixed load at a fixed position.  Knee positions were varied to get information 
at different muscle lengths.  The data showed higher extension torque production at 30° and 60° 
of knee flexion when compared to a knee position of 90° of flexion.  This was expected since 
muscle length-tension and patellar moment arm are maximized for performance at 45° of knee 
flexion.  All subjects increased their torque production over time with the highest amount of 
torque produced during the final week of testing.  The Botox™ subject was able to produce more 
isometric torque than the Placebo subjects at all data collection points.  The Botox™ subject also 
had a slight increase in torque production at week 4.  This is contrary to the expected affect of 
Botox™ and may have been due to a learning effect.  In fact, all subjects demonstrated this slight 
increase at week 4.  However, the case study comparison showed a difference between the 
Botox™ and Placebo treatments that disappeared by week 12. 
The Botox™ isokinetic and isometric results are consistent with a previous pilot study 
(Pidcoe, 2006).  The only difference is the magnitude of the measurements.  The pilot study was 
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performed on a single male subject who received Botox™ injects to the vastus lateralis muscles 
of both knees.  The current study ended up enrolling only women.  There was no effort to 
normalize data in these studies based on maximum voluntary force production, so the difference 
in force magnitude is probably due to gender.  The important point is the constituency of the 
results.  This provides validity to these results. 
 
Muscle balance (sEMG) 
Isometric and isokinetic testing are global measures of muscle performance.  They 
measure force production (or the result of muscle activation) at the distal end of the segment 
controlled by that muscle group.  In our case, the quadriceps muscles are activated to produce 
and knee extension force (or torque).  Muscles produce force as a result of an excitatory neural 
input.  This is an electrical event that results in an excitation-contraction coupling and a 
subsequent shortening of the muscle fibers.  The force produced is positively correlated to the 
electrical activity in the muscle and can be measured using surface electrodes.  Applying 
electrodes over the medial and lateral muscle groups allows an independent assessment of 
performance.  The collected data is described as surface electromyographic or sEMG. 
Medial (VMO) and lateral (VL) muscle sEMG data was collect from each subject while 
they performed isometric knee extension contractions.  The ratio of VMO:VL activation was 
computed and plotted.  A value of 1 would represent a balance between these muscles and equal 
electrical activity (or equivalent force production).  Since the captured electrical activity is a 
function of electrode placement, care was taken to standardize the methods based on previous 
published studies.  The consistent of the Placebo data suggests that the electrode placement was 
not an issue. 
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The VMO:VL ratios demonstrated an increase in VMO activation relative to VL in the 
subject treated with Botox™.  This difference was not evident by week 12 (the end of the study).  
The Placebo group showed no change in VMO:VL ratio.  
These results suggest that the Botox™ injection into VL was successful and decreased 
the electrical activity of that muscle.  Since electrical activity is correlated with force production, 
it is safe to say that force production of the VL also decreased.  This would result in a 
mechanical change in patellar tracking since both of these muscles attach to the patella and pull it 
in opposing directions.  Coupling these results with the subjective reports of decreased pain and 
improved function suggests a positive outcome for the Botox™ treatment.  These results are 
consistent with current physical therapy practice where efforts are made to modify patellar 
tracking to a more medial path in patients suffering from PFPS. 
 
Muscle Fatigue 
Another use of sEMG is to assess muscle fatigue.  Neuromuscular fatigue is defined as 
the inability of a muscle to produce force.  Muscles differ in fatigue rate secondary to intrinsic 
and extrinsic properties.  These can include muscle fiber type, the general health of the subject, 
nutrition, previous activity level, and genetics. It is expected that increased workloads will 
increase fatigue.  A work load can increase by increasing the external load or by decreasing the 
muscle fibers responsible for carrying that load.  When the VL muscle was injected with 
Botox™, it was expected that less fibers would be able to respond to neural excitation.  This was 
evidenced by comparing VMO:VL ratios and the general decrease in torque, work, and power 
production.  It was also expected that this would result in a higher fatigue rate in the VL, since 
fewer fibers would be doing the same amount of work. The fatigue analysis supports this 
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expectation.  The VL muscle had a higher fatigue rate in the Botox™ subject when compared to 
the Placebo subjects, while the VMO muscle results appeared unchanged. 
Muscles do not add fibers to become stronger.  In response to exercise, they do increase 
the efficiency of each fiber therefore fiber diameter is frequently increased.  This increase in 
muscle “tone” or density may have a mechanical impact on patellar tracking, although the exact 
ramifications are unknown.  It is possible that the reported decrease in pain by the Botox™ 
subject was due, in part, to a change in patellar tracking resulting from re-balancing the 
VMO/VL relationship.  It is also possible that the decrease in pain reported by all subjects was 
due, in part, to the overall effect of exercise on increasing muscle “tone”.  
 
Functional Testing 
Force plate 
Subjective VAS data was collected from subjects following a jumping task.  These data 
showed all subjects reported a decrease in perceived pain by the end of the study.  Objective data 
quantifying the jump were also collected.  Although there was a variation in the performance of 
the Placebo group, the important comparison is the case study results.  These showed that the 
Botox™ treatment resulted in a jump height 2.10 inches higher than the placebo treatment.  It is 
likely that this improvement was due to both increased muscle force production performance and 
decreased anterior knee pain. This study can not separate the underlying causes of the improved 
performance, but can only note that they are related.  Higher jumps require larger initiation 
forces; placing increased compression forces on the patellofemoral joint.  A decrease in pain 
would allow the subject to improve their performance.  
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Weekly Exercise 
 As part of the study protocol, subjects were asked to perform a home exercise program 
(HEP).  These exercises were part of a typical physical therapy regiment provided to patients 
with PFPS.  The use of closed chain exercises are an important component of the rehabilitation 
process.  Exercises like partial squats, have been reported by McConnell to prompt the highest 
activation of the VMO (O’Sullivan, 2005). 
During the course of the study, the subjects were asked to record the number of exercises 
they were able to perform and their perceived pain (with 0 = no pain and 10 = excruciating pain).  
They were also asked to increase the number of exercise repetitions as tolerated.  There progress 
was monitored by a licensed physical therapist. 
The typical pattern for the subject who received Botox was an increase in the number 
of repetitions and a decrease in pain from the beginning to the end of the study.  The Placebo 
subjects often had a similar trend in pain, but were unable to increase the number of repetitions 
in a prescribed exercise.  This has the potential to influence the long-term outcome of the 
treatment. 
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Chapter 5:  Conclusion 
 
 Since 1988, surgical lateral retinaculum release to relieve PFPS has been used with 
success.  Some believe the surgical release can treat both patella pain and some instability issues 
when used as a treatment for PFPS.  However, it is not only an invasive procedure in attempt to 
release excessive lateral pull on the patella, but surgically, it can also result in potential serious 
complications (Fox, 1993).  Therefore, non-invasive treatments should be considered to treat 
anterior knee pain.   
 The subject who received the Botox treatment experienced an improvement in 
functional activities with decreased pain.  These findings were consistent with a previous pilot 
study performed in the same laboratory.  The Placebo subjects showed less improvement or 
experienced no change in symptoms. 
As an alternative treatment, Botox offers a noninvasive treatment option.  The direct 
results of this study show perceived changes in pain during functional activities and an increase 
in tolerance to exercise.  Indirect results show a change in the balance of medial and lateral 
muscle groups that may lead to long-term functional improvement.  Balance of the knee extensor 
musculature is critical for optimal patella movement during knee extension (Sanchis-Alfonso, 
2006).  Restoring the balance of the quadriceps complex should assist in improving normal knee 
function. 
Despite the fact that the research was limited by the small number of participants, 
Botox was found to be safe and effective in treating anterior knee pain.   
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Future Work 
An ideal continuation of this study should include ten subjects with bilateral PFPS.  The 
double blind study should treat one limb with Botox and the contralateral limb with placebo 
control.  To address the study limitations, Botox treatment should be offered to those who 
receive the placebo control as an incentive to participate in the study.  This may offset the 
number of inquiries who only desire the Botox treatment option.  
Subjective questionnaires could be limited to include only LEFS, VAS, and possibly 
AKPS.  These metrics reported a clear difference between the two treatments.  Objective tests 
should continue to analyze the changes in kinetics and sEMG derivatives.   
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APPENDIX A 
1. Testing Script 
 
Patient: ###  
Date:     /   / 
 Start time: 
 End time: 
 Initiation:  Biodex, monitor, and computer on 
 Computer:  Motion monitor on: Joshua 
motion monitor for research, Botox, data acquisition, EMG data, view toolbars   new, 
set-up edit capture parameters- 10 secs record, autosave and add name  of file  
 Click:  Capture, record activity 
Position, velocity, force, EMG3(VL), EMG4(VM) [box #’s 3 and 4 labeled on the leads box] 
 
 Thank patient.    
Patient warm-up 5 minutes 50 watts, 50 rpm.  Leg positioning should be at 30° at end      of pedal 
stroke. 
 
 Explain process and to quickly move to the seat to begin testing while warm. 
  Seat #__13.0___________ 
 EMG placement- alcohol 
          leg extended : one handbreadth above patella (EMG3- lateralis) 
                       Four fingers above medial angle of the patella (EMG 4- medialis) 
 
Knee alignment   
Strap in: leg arm number __. 3048 m  12 on arm 
     NOTE: the bottom of the ankle pad is located 1 inch from medial malleolus 
 
ISOKINETIC 3 speed, knee, extension/flexion, concentric/concentric 
 set ROM range ___________ (should be close to 100-180 on Biodex screen  [10-90 
anatomically]) 
 
 verify 90°, set reference range to 10 and then 90  
limb weight (stop,enter,start to release leg) 
limb weight__________________ 
 
autoscale, 70%, 5 reps, (1 set first for warm-up) 
make sure speeds are set 1.  180°/s        and       180°/s            
Do one test run and make sure the strap is tight enough 
 
Change sets to three           
                           COUNT STOPS 
”ask patient to hit button when the red light hits at the end of each set      1. 
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            2.    90°/s                 180°/s           2. 
hit button          3. 
            3.    45°/s                   180°/s         
hit button 
5 reps and 3 sets – 60 sec rest 
ISOMETRIC agonist 
 verify 90° & set reference to 30° or  set ROM @ 120 ±2 = 30 degree 
limb weight (stop,enter,start to release leg) 
limb weight__________________ 
autoscale, 70%, 5 reps, 3 sets 
hit button after each set 
60 sec rest                                                                                               COUNT STOPS 
 set-up, standby, change ROM to 150 = 60 degrees   1. 
 limb weight ____________, autoscale, 70%, 5 reps, 3 sets  2.           set-
up, standby, change ROM to 90 degrees     3.          limb weight 
____________, autoscale, 70%, 5 reps, 3 sets 
 ESC, ESC, GO to reports, check current date, evaluations, generate reports, F4, max average 
for ft-lbs, hit F1 to print (see example of print out below).  Calculate avg. for 150 (60°) patient 
average _________________ 
 
hit done on motion monitor, set-up, capture parameters, change period to 50 seconds, change 
file name 
 
FATIGUE TESTING 
 verify 90°, set ROM at 150 (60° position), 40 seconds, 1 rep, at 80%, place average from 
isometric testing at (60°) 
 limb weight_____________ 
Tell patient to aim at the bottom of the line and try to hold it for the 40 seconds 
***patient doesn’t start 2nd set of fatigue until hour glass is off the motion monitor,  Don’t go by 
stop lights.*** 
 Ask patient to hit button after 1 set.    COUNT STOPS 
Repeat, stop 
Repeat, stop        1. 
          2. 
          3. 
To export: analyze, export, multiple users, user report 
C:programfiles:innsport-motion monitor/ user/ Botox/ export 
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2. Example Printout from the Biodex for Isometric Testing 
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3. Sample of Week 12 Checklist 
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4. Example of the End of the study Questionnaire 
 
 
5. Subject Anthropometric data 
 
Height (inches) 66 63 66 63 
Weight (pounds) 128 116 128 105 
Moment Arm (meters) 0.3048 0.2794 0.3048 0. 2794 
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6. Anterior Knee Pain Scale Results 
 Botox ™ Placebo 1 Placebo 2 Placebo 3 
Session 1 75 57 73 69 
Session 2 76 60 79 83 
Session 3 77 69 85 73 
Session 4 95 72 81 91 
Change in Score +20 +15 +8 +22 
 
 
7. Functional Index Questionnaire Results.  Each question is scored from 0-2, unable to do - 
no problem (Harrison, 1995).  
 
 Botox ™ Placebo 1 Placebo 2 Placebo 3 
Task                  Session 1,2,3,4 1,2,3,4 1,2,3,4 1,2,3,4 
Walking 1 mile 2,2,2,2 1,1,2,2 2,2,2,2 1,1,1,1 
Climbing 16 steps 1,2,1,2 1,1,1,2 1,1,1,2 1,2,2,2 
Squatting 1,1,1,1 1,1,1,2 1,1,1,1 2,1,1,1 
Kneeling 2,1,1,1 1,1,1,2 1,1,1,1 2,1,1,2 
Prolonged sitting with 
knees bent 
1,1,1,1 1,1,1,2 1,1,1,1 1,1,1,1 
Climbing 32 steps 1,1,1,2 1,1,1,2 1,1,1,2 1,2,2,2 
100 meter short run 1,2,2,2 1,1,1,2 2,2,2,2 1,1,2,2 
Waking 1 city block 2,2,2,2 1,1,2,2 2,2,2,2 2,2,2,2 
Total 11,12,11,13 8,8,10,16 11,11,11,13 11,11,12,13 
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8. The Lower Extremity Functional Scale Results in percentage.   
A score of 100% represents no difficulty with usual work, hobbies, bathing, walking, 
putting on shoes, squatting, lifting objects from the floor, performing light activities, 
getting in/out of car, walking 2 block to a mil, ascending/descending 10 stairs, standing 
and sitting for 1 hour, running on uneven ground, making sharp turns while running fast, 
hopping, and rolling out of bed.  
 
 
 Botox™ Placebo 1 Placebo 2 Placebo 3 
Session 1 69 51 80 69 
Session 2 87 63 79 71 
Session 3 87 65 86 68 
Session 4 91 59 81 85 
 
 
 
 
9. Botox Subject: Work and Power results 
Botox Subject   
WORK Power 
  180° 90° 45°     180° 90° 45° 
1 5539 9181 14020   1 4171 3580 2736 
4 1042 1562 3005   4 3438 3333 2696 
6 2257 4085 5592   6 7365 6221 4073 
12 1297 3038 4024   12 4809 5536 3260 
Std 
deviation         
Std 
deviation       
1 98 175 436   1 269 155 85 
4 178 332 989   4 617 651 945 
6 179 373 293   6 585 598 145 
12 221 205 589   12 513 449 589 
 
 
 
    
 
 
 
77
Placebo 1: Work and Power results 
Placebo 1    
WORK Power 
  180° 90° 45°     180° 90° 45° 
1 3834 42 989   1 8823 71 200 
4 120 153 191   4 96 60 38 
6 103 197 219   6 80 76 42 
12 38 50 55   12 13 9 58 
Std 
deviation         
Std 
deviation       
1 883 313 436   1 4460 155 85 
4 17 6 12   4 13 5 2 
6 17 22 28   6 13 9 5 
12 5 1 6   12 18 3 21 
 
 
 
Placebo 2: Work and Power results 
Placebo 2   
WORK Power 
  180° 90° 45°     180° 90° 45° 
1 2059 3657 5356   1 5465 5498 3829 
4 2120 3075 4958   4 6750 5539 3577 
6 1920 3733 5891   6 6833 5761 4125 
12 2773 5130 6216   12 8983 7505 4282 
Std 
deviation         
Std 
deviation       
1 333 337 759   1 1166 543 755 
4 512 294 3511   4 1620 581 2394 
6 279 526 310   6 1106 843 228 
12 420 269 611   12 1546 352 261 
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Placebo 3: Work and Power results 
Placebo 3  
WORK Power 
  180° 90° 45°     180° 90° 45° 
1 2120 3883 4803   1 7033 6424 3839 
4 4297 5108 5250   4 13953 7887 3925 
6 4066 5288 5119   6 14682 8397 3902 
12 3764 5321 5695   12 14283 8949 4568 
Std 
deviation         
Std 
deviation       
1 323 345 380   1 1180 539 305 
4 133 378 272   4 561 546 165 
6 276 274 826   6 953 388 727 
12 95 246 319   12 913 518 382 
 
 
10. Isometric torque Results in Nm for all study subjects. 
 
Botox™ 30° 60° 90° Placebo 1 30° 60° 90° 
1 26 56 59 1 30 55 49 
4 57 78 87 4 45 59 57 
6 43 73 73 6 40 61 59 
12 37 77 75 12 41 64 61 
Placebo 2 30° 60° 90° Placebo 3 30° 60° 90° 
1 19 50 60 1 45 51 54 
4 51 39 82 4 35 63 63 
6 36 75 81 6 41 69 67 
12 38 73 84 12 48 77 75 
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11. EMG ratios of VMO/VL 
Botox™ 30° 60° 90° Placebo 1 30° 60° 90° 
1 0.91 0.66 0.54 1 0.68 0.69 0.80 
4 NA NA NA 4 1.00 0.87 0.82 
6 0.54 0.52 0.43 6 0.47 0.51 0.45 
12 0.55 0.60 0.57 12 0.97 0.88 0.79 
Placebo 2 30° 60° 90° Placebo 3 30° 60° 90° 
1 0.44 0.47 0.41 1 0.68 0.61 0.57 
4 0.33 0.36 0.34 4 0.50 NA NA 
6 0.37 0.39 0.30 6 0.66 0.70 0.85 
12 0.33 0.29 0.36 12 0.76 0.74 0.62 
 
 
12. Force plate results with flight time during a vertical jump (in seconds). 
 Botox™ Placebo 1 Placebo 2 Placebo 3 
Week 1 359 413 387 430 
Std Dev 3.21 43.6 3.54 31.9
Week 4 392 485 381 374 
Std Dev 2.03 22.2 1.41 68.7
Week 6 381 473 377 458 
Std Dev 3.06 4.62 3.54 9.54
Week 12 408 477 382 445 
Std Dev 21.7 12.5 5.66 6.56
 
13. Summary of Botox Subjects’ weekly exercise results 
 
 
 
Weekly exercise report for Placebo 1 
Botox Single Limb 
Squat 
Squat with 
adduction ITB stretch 
Side lying 
Abduction 
Straight leg 
raise 
Side raise 
Adduction 
week reps / pain reps / pain reps/ pain reps / pain reps / pain reps / pain 
1 2 / 6 2 / 6 10 / 1 2 / 5 2 / 7 2 / 4 
2 3 / 4 2 / 4 10 / 0 2 / 3 2 / 5 2 / 4 
4 3 / 1 3 / 3 10 / 0 3 / 4 3 / 5 3 / 4 
6 4 / 1 3 / 2 10 / 0 3 / 2 3 / 4 3 / 4 
8 5 / 1 3 / 2 10 / 0 3 / 2 3 / 2 3 / 2 
10 6 / 1 3 / 1 10 / 0 3 / 1 3 / 1 3 / 1 
12 7 / 1 3 / 1 10 / 0 3 / 1 3 / 2 3 / 1 
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Placebo 
1 Single 
Limb Squat 
Squat with 
adduction ITB stretch 
Side lying 
Abduction 
Straight leg 
raise 
Side raise 
Adduction 
week reps / pain reps / pain reps/ pain reps / pain reps / pain reps / pain 
1 2 / 7 2 / 5 10 / 7 3 / 4 3 / 6 3 / 5 
2 3 / 5 2 / 3 10 / 4 3 / 3 3 / 5 3 / 4 
4 3 / 1 3 / 0 10 / 1 3 / 0 3 / 3 3 / 1 
6 3 / 3 3 / 0 10 / 2 3 / 1 3 / 2 3 / 1 
8 2 / 0 2 / 2 10 / 1 3 / 0 3 / 0 3 / 0 
10 3 / 3 3 / 2 10 / 0 3 / 0 3 / 0 3 / 0 
12 3 / 2 2 / 2 10 / 0 3 / 1 3 / 2 3 / 2 
 
Weekly exercise report for Placebo 2 
Placebo 
2 Single 
Limb Squat 
Squat with 
adduction ITB stretch 
Side lying 
Abduction 
Straight leg 
raise 
Side raise 
Adduction 
week reps / pain reps / pain reps/ pain reps / pain reps / pain reps / pain 
1 2 / 4 2 / 5 10 / 2 2 / 5 2 / 6 2 / 5 
2 2 / 3 2 / 4 10 / 2 2 / 5 2 /6 2 / 7 
4 2/ 2 2 / 3 10 / 2 2 / 5 2 / 5 2 / 4 
6 3 / 3 2 / 3 10 / 2 2 / 5 2 / 4 2 / 4 
8 3 / 1 3 / 2 10 / 2 2 / 4 2 / 4 2 / 4 
10 3 / 2 3 / 1 10 / 2 2 / 3 2 / 3 2 / 3 
12 3 / 2 3 / 2 10 / 2 2 / 2 2 / 2 2 / 2 
 
Weekly exercise report for Placebo 3 
Placebo 
3 Single 
Limb Squat 
Squat with 
adduction ITB stretch 
Side lying 
Abduction 
Straight leg 
raise 
Side raise 
Adduction 
week reps / pain reps / pain reps/ pain reps / pain reps / pain reps / pain 
1 3 / 1 3 / 1 10 / - 3 / 2 3 / 5 3 / 4 
2 3 / 0 3 / 1 10 / - 3 / 2 3  /3 3 / 2 
4 3 / 0 3 / 0 10 / - 3 / 0 3 / 0 3 / 1 
6 3 / 3 3 / 3 10 / - 3 / 3 3 / 3 3 / 3 
8 3 / 1 3 / 1 10 / - 3 / 2 3 / 2 3 / 2 
10 3 / 1 3 / 1 10 / - 3 / 1 3 / 1 2 / 1 
12 3 / 0 3 / 0 10 / - 3 / 1 3 / 1 3 / 0 
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APPENDIX B 
CALIBRATION PLOTS 
 
A    
B   
 C  
 
Calibration plots for Biodex used in Matlab programs.  Plots A, B, and C are the position, 
velocity and torque respectively.  Calibrations for force, position, and velocity were performed 
using a simple oscilloscope, and voltmeter.  These calibrations convert from a voltage source to a 
real world degree, degree per second and torque (Nm) during testing sessions.   
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APPENDIX C 
 
A.  Isokinetic Program 
%--------------------------------------------- 
%  This program is designed to calibrate the  
%  pos, vel, and force data 
%  PEP 101007 
%--------------------------------------------- 
clear all                                     % clear all variables 
close all                                     % close all windows and files 
X=input('Select File to Run: ','s'); 
Y=load(X); 
pos_V=Y(:,2); 
vel_V=Y(:,3); 
force_V=Y(:,4); 
VL_emg=Y(:,5); 
VMO_emg=Y(:,6); 
file_len=length(pos_V); 
RADIAN=3.14/180; 
 
ma=input('Enter moment arm: '); 
%ma=.34; 
 
%--------------------------------------------- 
%  create arrays 
%--------------------------------------------- 
pos_RW=zeros(file_len,1); 
vel_RW=zeros(file_len,1); 
torque_RW=zeros(file_len,1); 
work=zeros(file_len,1); 
power=zeros(file_len,1); 
 
segment=zeros(15,1); 
%ave_vel=zeros(15,1); 
%ave_work=zeros(15,1); 
%ave_power=zeros(15,1); 
%max_vel=zeros(15,1); 
%--------------------------------------------- 
%  convert data 
%--------------------------------------------- 
for i=1:file_len 
   pos_RW(i)=(-19.225*pos_V(i))+169.25;  
   vel_RW(i)=(45.557 * vel_V(i))+0.7484; 
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   force_RW=-((-182.36*force_V(i))-14.053);  % invert force values 
   torque_RW(i)=force_RW * ma; 
   work(i)=torque_RW(i)*(pos_RW(i)*RADIAN); 
   power(i)=torque_RW(i)*(vel_RW(i)*RADIAN); 
end 
 
%--------------------------------------------- 
%  find concentric segments of data 
%--------------------------------------------- 
k = 1; 
loop_len = 5; 
flag = 0; 
stop = 0; 
start=1; 
 
%-------------------------------------------------------------------------- 
%  Plot results to confirm appropriate selection of data 
%-------------------------------------------------------------------------- 
figure('Name','Torque and EMG Data Window','NumberTitle','off') 
 
% Plot results 
subplot(3,1,1) 
  hold off 
  plot(pos_RW,'b') 
    title('Position') 
    ylabel('deg') 
  hold on 
subplot(3,1,2) 
  hold off 
  plot(torque_RW,'b') 
    title('Torque') 
    ylabel('lbs-ft?') 
  hold on 
subplot(3,1,3) 
  hold off 
  plot(vel_RW,'b') 
    title('Velocity') 
    ylabel('deg/sec') 
  hold on 
%-------------------------------------------------------------------------- 
%  Continue processing data and 1st pass segment bounds. 
%-------------------------------------------------------------------------- 
while (stop == 0) 
skip = 0; 
for i=start:file_len-loop_len 
    if (i == file_len-loop_len) 
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        stop = 1; 
    end 
    flag = 0; 
if (skip == 0)   
  for j=1:loop_len-1 
    if (vel_RW(i+j) > vel_RW(i+j-1) && vel_RW(i+j) > 10) 
       flag = flag + 1; 
    end 
  end 
  if (flag == loop_len-1) %found a concentric segment 
    for m=i+j:-1:1 
       if (vel_RW(m) <= 0 && flag == loop_len-1) 
             segment(k) = m; 
             %vel_RW(m); 
             %flag 
             k=k+1; 
             flag = -1; 
       end 
     end 
  end 
  if (flag == -1) %found beginning concentric, now wait till end to search for next  
    for n=segment(k-1)+1:file_len 
        if (vel_RW(n) <= 0 && flag == -1) 
            segment(k) = n; 
            k=k+1; 
            flag = 0; 
            start=n; 
            skip = 1; 
        end 
        if (n >= file_len) % stop if no end of segment found 
            flag = 0; 
            k=k-1; 
        end 
        if (flag == 0) 
            break 
        end 
    end 
  end 
if (skip == 1) 
    break 
end 
end 
end 
number = (k-1)/2    %display number of segment 
segment (1:number*2,1)  %display segment boundaries  
%-------------------------------------------------------------------------- 
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%  Plot the 1st pass segment bounds. 
%-------------------------------------------------------------------------- 
for i=1:number*2 
    x = [segment(i) segment(i)]; plot(x,ylim,'r')      % ylim = axis limits 
end 
%-------------------------------------------------------------------------- 
%  Improve segment bounds estimates. Use the middle 50 points of each 
%  velocity segment to determine the base standard deviation. Set a 
%  decision threshold at 2x that value. Starting from the middle of a 
%  segment and progressing outward in both directions, compute the standard 
%  deviation and when it exceeds the threshold, the new segment bounds are 
%  stored (replacing the old values). 
%-------------------------------------------------------------------------- 
for i=1:2:number*2 
    half_len = int16((segment(i+1) - segment(i))/2-25); % center +/- 25 pts 
    for j=half_len:-1:1 
        start = segment(i)+j-1; 
        stop = segment(i+1)-j-1; 
        stdev = std(vel_RW(start:stop)); 
        if (j == half_len) 
            threshold = stdev *2;                  % threshold at 2 x stdev 
        end 
        if (stdev > threshold) 
            segment(i) = start;                    % set new start value 
            segment(i+1) = stop;                   % set new stop value 
            break; 
        end 
    end 
end 
%-------------------------------------------------------------------------- 
%  Plot the 2nd pass segment bounds (in green). 
%-------------------------------------------------------------------------- 
for i=1:number*2 
    x = [segment(i) segment(i)]; plot(x,ylim,'g')      % ylim = axis limits 
end 
segment (1:number*2,1)  %display segment boundaries 
%-------------------------------------------------------------------------- 
%  calculate maximum velocity, average velocity, work and power for 
%  concentric knee extension 
%-------------------------------------------------------------------------- 
k=1; 
for i=1:2:number*2 
    ave_work(k) = mean(work(segment(i):segment(i+1))); 
    ave_power(k) = mean(power(segment(i):segment(i+1))); 
    ave_vel(k) = mean(vel_RW(segment(i):segment(i+1))); 
    max_vel(k) = max(vel_RW(segment(i):segment(i+1))); 
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%    for j=segment(i):segment(i+1) 
%      ave_work(k) = ave_work(k) + work(j); 
%      ave_power(k) = ave_power(k) + power(j); 
%      ave_vel(k) = ave_vel(k) + vel_RW(j); 
%      if (vel_RW(j) > max_vel(k)) 
%        max_vel(k) = vel_RW(j); 
%      end 
%    end 
%   ave_vel(k) = ave_vel(k) / (segment(i+1)-segment(i)); 
%   ave_work(k) = ave_work(k) / (segment(i+1)-segment(i)); 
%   ave_power(k) = ave_power(k) / (segment(i+1)-segment(i)); 
   k=k+1; 
end 
t_work = 0; 
t_power = 0; 
for i=1:number 
   t_work = ave_work(i); 
   t_power = ave_power(i); 
end 
t_work = t_work / number; 
t_power = t_power / number; 
%--------------------------------------------- 
%  save data 
%--------------------------------------------- 
out=strcat(X,'.cal'); 
export=[pos_RW vel_RW torque_RW work power]; 
double(export); 
save(out, 'export', '-ascii', '-tabs'); 
out2=strcat(X,'.ave'); 
%export=[number t_work t_power]; 
%double(export); 
%save(out2, 'export', '-ascii', '-tabs'); 
%CHANGE BACK TO COLUMAR DATA OUTPUT -- PEP 021308 
export=[max_vel(1:number)' ave_vel(1:number)' ave_work(1:number)' 
 ave_power(1:number)']; 
%export=[max_vel ave_vel ave_work ave_power]; 
double(export); 
save(out2, 'export', '-ascii', '-tabs'); 
 
B.  Isometric Program 
%-------------------------------------------------------------------------- 
%  ISOMETRIC.M --  
%  This program is designed to calibrate the position, velocity, and torque 
%  data. It determines the location of the isometric segment in the data 
%  stream and computes the max, min, and average of that segment. It also 
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%  computes the RMS EMG for the VMO and VL muscles. All data is restored in 
%  text file format. 
%  PEP 020408 
%-------------------------------------------------------------------------- 
clear all                                     % clear all variables 
close all                                     % close all windows and files 
X=input('Select File to Run: ','s'); 
Y=load(X); 
pos_V=Y(:,2); 
vel_V=Y(:,3); 
force_V=Y(:,4); 
VL_emg=Y(:,5); 
VMO_emg=Y(:,6); 
file_len=length(pos_V); 
RADIAN=3.14/180; 
ma=input('Enter moment arm: '); 
%ma=.34; 
uthresh = input('Enter data start position: '); 
if (isempty (uthresh))              % set variable to 1 if no value entered 
    uthresh = 1; 
end 
%-------------------------------------------------------------------------- 
%  create arrays 
%-------------------------------------------------------------------------- 
pos_RW=zeros(file_len,1); 
vel_RW=zeros(file_len,1); 
torque_RW=zeros(file_len,1); 
work=zeros(file_len,1); 
power=zeros(file_len,1); 
segment=zeros(15,1); 
ave_vel=zeros(15,1); 
ave_work=zeros(15,1); 
ave_power=zeros(15,1); 
max_vel=zeros(15,1); 
%-------------------------------------------------------------------------- 
%  convert data 
%-------------------------------------------------------------------------- 
for i=1:file_len 
   pos_RW(i)=(-19.225*pos_V(i))+169.25-180;  
   vel_RW(i)=(45.557 * vel_V(i))+0.7484; 
   force_RW=-((-182.36*force_V(i))-14.053);  % invert force values 
   torque_RW(i)=force_RW * ma; 
   work(i)=torque_RW(i)*(pos_RW(i)*RADIAN); 
   power(i)=torque_RW(i)*(vel_RW(i)*RADIAN); 
end 
%-------------------------------------------------------------------------- 
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%  determine baseline mean and stdv in first 250ms of torque data -- the 
%  controlling variable is baseline_size and is initially set to 25 
%-------------------------------------------------------------------------- 
baseline_size = 250; 
average = mean(torque_RW(1:baseline_size)); 
standard_dev = std(torque_RW(1:baseline_size)); 
%-------------------------------------------------------------------------- 
%  find isometric segment -- Note: use max torque value as condition to 
%  help find end of segment 
%-------------------------------------------------------------------------- 
flag = 0; 
file_max = max(torque_RW); 
iso_start = 0; 
iso_stop = 0; 
threshold = average + (4 * standard_dev); 
scnt = 500; % start value must exceed threshold for 0.5s (sampled @ 1000Hz) 
if (uthresh > 1) 
    baseline_size = uthresh; % set start of search to user defined position 
end 
for i=baseline_size:file_len 
    if (torque_RW(i) >= file_max) 
        flag = 1; 
    end 
    if (iso_start == 0 && torque_RW(i) > threshold) 
%        iso_start = i; 
        cnt = 0; 
        for j=i+1:file_len            % look for consistently met threshold 
            if (torque_RW(j) > threshold) 
                cnt = cnt + 1; 
            else 
                break; 
            end 
            if (cnt >= scnt) 
                iso_start = i; 
                break; 
            end 
         end 
    end 
    if (iso_stop == 0 && iso_start > 0 && torque_RW(i) < threshold && flag == 1) 
        iso_stop = i; 
    end 
end 
if iso_stop == 0 
    iso_stop = file_len;                     % set end to EOF if none found 
end 
iso_time = (iso_stop - iso_start) / 1000;                     % to be saved 
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% Define figure and start plot 
figure('Name','Torque and EMG Data Window','NumberTitle','off') 
subplot(3,1,1) 
  hold off 
  plot(torque_RW,'b') 
    title('Torque') 
    ylabel('Nm') 
  hold on 
  x = [iso_start iso_start]; plot(x,ylim,'r')   % ylim provides axis limits 
  x = [iso_stop iso_stop];   plot(x,ylim,'r')   % ylim provides axis limits 
%-------------------------------------------------------------------------- 
%  compute isometric torque max, min, and average values 
%-------------------------------------------------------------------------- 
max_torque = max(torque_RW(iso_start:iso_stop));              % to be saved 
min_torque = min(torque_RW(iso_start:iso_stop));              % to be saved 
ave_torque = mean(torque_RW(iso_start:iso_stop));             % to be saved 
%-------------------------------------------------------------------------- 
%  EMG processing 
%-------------------------------------------------------------------------- 
% Determine EMG baseline (for same amount of data used in torque baseline %above 
VL_average = mean(VL_emg(1:baseline_size)); 
VMO_average = mean(VMO_emg(1:baseline_size)); 
% Subtract baseline from raw EMG data and compute RMS data 
for i=1:file_len 
    VL_emg_BL = VL_emg(i) - VL_average; 
    VMO_emg_BL = VMO_emg(i) - VMO_average 
    VL_rms(i) = sqrt(VL_emg_BL * VL_emg_BL); 
    VMO_rms(i) = sqrt(VMO_emg_BL * VMO_emg_BL); 
end 
% Use time constant (TAU) to smooth the data 
tau = 250;                        % 25ms equivalent at 1000Hz sampling rate 
half_tau = floor(tau / 2);        % round down 
for i=half_tau+1:file_len-half_tau 
    VL_filt(i) = mean(VL_rms(i-half_tau:i+half_tau)); 
    VMO_filt(i) = mean(VMO_rms(i-half_tau:i+half_tau)); 
end 
for i=1:half_tau                                         % fill in the ends 
    VL_filt(i) = VL_filt(half_tau+1); 
    VMO_filt(i) = VMO_filt(half_tau+1); 
end 
for i=file_len-half_tau+1:file_len                       % fill in the ends 
    VL_filt(i) = VL_filt(file_len-half_tau); 
    VMO_filt(i) = VMO_filt(file_len-half_tau); 
end 
% Determine average RMS during isometric hold 
ave_VL = mean(VL_filt(iso_start:iso_stop));                   % to be saved 
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ave_VMO = mean(VMO_filt(iso_start:iso_stop));                 % to be saved 
% Plot results 
subplot(3,1,2) 
  hold off 
  plot(VL_rms,'b') 
    title('VL') 
    ylabel('v') 
  hold on 
  plot(VL_filt,'r') 
subplot(3,1,3) 
  hold off 
  plot(VMO_rms,'b') 
    title('VMO') 
    ylabel('v') 
  hold on 
  plot(VMO_filt,'r') 
%pause; 
%-------------------------------------------------------------------------- 
%  save data (results and processed data) 
%-------------------------------------------------------------------------- 
fid = fopen(strcat(X,'.emg'),'w'); 
  fprintf(fid,'%s\n',X); 
  fprintf(fid,'iso time   = \t%.3f\t sec\n',iso_time); 
    fprintf(fid,'start = \t%.3f\t sec\n',iso_start/1000); 
    fprintf(fid,'stop = \t%.3f\t sec\n\n',iso_stop/1000); 
  fprintf(fid,'ave torque = \t%.3f\t Nm\n',ave_torque); 
    fprintf(fid,'max_torque = \t%.3f\t Nm\n',max_torque); 
    fprintf(fid,'min_torque = \t%.3f\t Nm\n\n',min_torque); 
  fprintf(fid,'ave VL  = \t%.3f\n',ave_VL); 
  fprintf(fid,'ave VMO = \t%.3f\n',ave_VMO); 
fclose(fid); 
out=strcat(X,'.emg_data.xls'); 
export=[transpose(VL_rms(1:file_len)) transpose(VL_filt(1:file_len)) 
transpose(VMO_rms(1:file_len)) transpose(VMO_filt(1:file_len))]; 
double(export); 
save(out, 'export', '-ascii', '-tabs'); 
 
 
C.  Fatigue Program 
%  FATIGUE (botox) 
clear all                                     % clear all variables 
close all                                     % close all windows and files 
sampling_rate = 1000;              % set to 1000Hz 
interval = 1 / sampling_rate; 
X=input('Select File to Run: ','s'); 
Y=load(X); 
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pos_V=Y(:,2); 
vel_V=Y(:,3); 
force_V=Y(:,4); 
VL_emg=Y(:,5); 
VMO_emg=Y(:,6); 
file_len=length(pos_V); 
% REMOVE OFFSET FROM DATA 
VL_emg = VL_emg - mean(VL_emg); 
VMO_emg = VMO_emg - mean(VMO_emg); 
% END REMOVE OFFSET 
%-------------------------------------------------------------------------- 
%  Find start (t1) and stop (t2) of the usable EMG data based on force 
%  data. 
%-------------------------------------------------------------------------- 
t1 = 0; 
t2 = 0; 
threshold = max(force_V) * .5;       % threshold @ 50 percent 
for i=1:file_len 
    if (t1 == 0 && force_V(i) >= threshold)             % find start 
        t1 = i; 
    end 
    if (t1 > 0 && t2 == 0 && force_V(i) < threshold)  % find stop 
        if (i > t1+5000)               % added to reduce false stops 
            t2 = i; 
        end 
    end  
end 
if (t2 == 0)                           % define stop as EOF if none found 
    t2 = file_len; 
end 
%-------------------------------------------------------------------------- 
%  Plot raw data. 
%-------------------------------------------------------------------------- 
close all; 
figure('Name','RAW EMG Data Window','NumberTitle','off') 
% CREATE TIME ARRAY FOR PLOTTING 
cnt=1; 
while cnt <= file_len 
  xtime(cnt) = (cnt-1)*interval; 
  cnt = cnt + 1; 
end 
%  PLOT RAW DATA 
hold off   
plot(xtime,VL_emg,'b') 
str = sprintf('Raw Data (VL)'); 
    title(str) 
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    xlabel('time') 
    ylabel('volts') 
hold on 
    % overplot start and stop 
x = [t1*interval t1*interval]; plot(x,ylim,'r') % ylim = axis limits 
x = [t2*interval t2*interval]; plot(x,ylim,'r') % ylim = axis limits 
pause(3); 
hold off 
%-------------------------------------------------------------------------- 
%  Compute median freq for segments of EMG using and overlap method 
%-------------------------------------------------------------------------- 
fft_len = 512; 
count=1; 
    start = t1; 
    stop = t1+fft_len-1; 
while stop < t2 
    Raw = VL_emg(start:stop); 
% NEW FFT WAY!!! 
%array_len = length(Y); 
%half_len = int16(array_len / 2); 
Y=fft(Raw); 
YY=Y.*conj(Y)/length(Y); 
f=1000*(0:length(Y)/2)/length(Y); 
figure('Name','Data','NumberTitle','off') 
subplot(2,1,1) 
    plot(xtime,VL_emg,'b') 
    str = sprintf('Raw Data (VL)'); 
        title(str) 
        xlabel('time') 
        ylabel('volts') 
    hold on 
    istart = start*interval 
    istop = stop*interval 
    x = [istart istart]; plot(x,ylim,'r');           % ylim = axis limits 
    x = [istop istop]; plot(x,ylim,'r');             % ylim = axis limits 
hold off 
subplot(2,1,2) 
    plot(f(1:int16(length(Y)/2)),YY(1:int16(length(Y)/2)),'b') 
    hold on; 
% END NEW FFT WAY 
% COMPUTE MEDIAN FREQUENCY 
cnt = length(Y)/2+1; 
sum = 0; 
for i=1:cnt 
    sum = sum + (1 * YY(i)); 
end 
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half_sum = sum/2;  sum = 0; 
i=1; 
while sum <= half_sum 
    sum = sum + (1 * YY(i)); 
    median_freq(count) = f(i); 
    i = i + 1; 
end 
count; 
median_freq(count); 
x = [median_freq(count) median_freq(count)]; plot(x,ylim,'r');       % ylim = axis limits 
    str = sprintf('FFT (VL) median freq = %.2f',median_freq(count)); 
        title(str) 
        xlabel('freq') 
        ylabel('amplitude') 
hold off; 
% END COMPUTE MEDIAN FREQUENCY 
count=count+1; 
pause(2); 
close all; 
clf; 
    j = stop+1 - (fft_len/2); 
    start = j; 
    stop = j+fft_len-1; 
end 
%-------------------------------------------------------------------------- 
%  Plot median frequencies 
%-------------------------------------------------------------------------- 
close all; 
figure('Name','Fatigue Analysis','NumberTitle','off') 
% CREATE TIME ARRAY FOR PLOTTING 
cnt=1; 
clear xaxis; 
while cnt < count 
  xaxis(cnt) = (cnt-1); 
  cnt = cnt + 1; 
end 
%  PLOT RAW DATA 
plot(xaxis,median_freq,'b') 
str = sprintf('Median Frequency'); 
    title(str) 
    xlabel('count') 
    ylabel('Hz') 
pause(3); 
%-------------------------------------------------------------------------- 
%  Open a data storage file & store median frequency 
%-------------------------------------------------------------------------- 
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out=strcat(X,'.fat'); 
export=[median_freq]'; 
double(export); 
save(out, 'export', '-ascii', '-tabs'); 
close all; 
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APPENDIX D 
 
A.  Patellofemoral Pain Study Pre-Study Questionnaire  
Name  
Age:  
Do you have:  
Knee pain: Yes No  
If yes is your knee pain on the Right or Left  
Rate your knee pain on a scale of 0 – 10 (0 no pain, 10 the worst pain you can imagine) ______  
Did your pain begin as the result of trauma/injury or did it begin gradually  
Have you ever had knee surgery on this knee: Yes No  
Has your patellar (kneecap) ever dislocated Yes No  
 
Describe your knee pain in relation to your kneecap ie behind, below, to the inside or outside of 
the kneecap  
 
Do you have this pain while (put an X next to each one that you answer yes to)  
_____ prolonged sitting,  
_____ climbing stairs,  
_____ squatting,  
_____ running,  
_____ kneeling,  
_____ hopping,  
_____ jumping.  
 
How long have you had this knee pain _______  
 
Have you ever had an allergic reaction to Botulinum toxin A (Botox) injection Yes No  
 
Please list all known allergies:  
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B.  Patellofemoral Pain Pre-Study Evaluation  
 
 
C.  Patellofemoral Pain Prior Perceived pain 
 
Date: __________________________  
Subject Number: ____________  
 
  
No Pain___________________________________________________________ Worst Pain  
         
 
For the Usual amount of pain you have had today  
 
Indicate on the line where the pain is in relation to the two extremes  
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D.  First preliminary Patellofemoral Pain study visit  
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E.  LEFS  Form 
 
F.  Patellofemoral Pain VAS for ascending, descending, and jumping 
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G.  Patellofemoral Pain VAS for great and usual Pain 
 
  
  
    
 
 
 
100
 
VITA 
 
Laura Maple was born and raised in Virginia in January 1980.  She is a United States citizen who 
has attending Louisburg College in North Carolina and Virginia Commonwealth University.  She 
earned her bachelor’s of Science at VCU in Chemistry while being on the Dean’s List and a 
member of the National Chemical Society.  She was awarded as the recipient of the Ingraham 
Scholarship. Since graduating from undergraduate school Laura has published in the Journal of 
American Society for Mass Spectrometry, “Evaluation of Sample Preparation Techniques for 
mass measurements of PCR products using ESI-FT- ICR Mass Spectrometry and in Drug 
Monitoring and Toxicology, for Development and validation of ELISA for Herceptin detection 
in human serum. 
   
  
 
 
 
 
 
